JPS638399A - Physiologically active polypeptide - Google Patents
Physiologically active polypeptideInfo
- Publication number
- JPS638399A JPS638399A JP61151773A JP15177386A JPS638399A JP S638399 A JPS638399 A JP S638399A JP 61151773 A JP61151773 A JP 61151773A JP 15177386 A JP15177386 A JP 15177386A JP S638399 A JPS638399 A JP S638399A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- mrna
- cdna
- cells
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 31
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 30
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 abstract description 69
- 239000002299 complementary DNA Substances 0.000 abstract description 52
- 108020004999 messenger RNA Proteins 0.000 abstract description 46
- 230000000694 effects Effects 0.000 abstract description 34
- 238000000034 method Methods 0.000 abstract description 32
- 241000282414 Homo sapiens Species 0.000 abstract description 27
- 108091008146 restriction endonucleases Proteins 0.000 abstract description 19
- 102000004083 Lymphotoxin-alpha Human genes 0.000 abstract description 18
- 108090000542 Lymphotoxin-alpha Proteins 0.000 abstract description 18
- 239000013612 plasmid Substances 0.000 abstract description 17
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 14
- 239000000523 sample Substances 0.000 abstract description 14
- 239000013598 vector Substances 0.000 abstract description 14
- 241000588724 Escherichia coli Species 0.000 abstract description 13
- 102100034343 Integrase Human genes 0.000 abstract description 9
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 230000007910 cell fusion Effects 0.000 abstract description 3
- 238000002523 gelfiltration Methods 0.000 abstract description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 abstract description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 26
- 239000000243 solution Substances 0.000 description 24
- 239000002585 base Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 239000000872 buffer Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 238000005119 centrifugation Methods 0.000 description 14
- 210000004408 hybridoma Anatomy 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 210000000287 oocyte Anatomy 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 108010062580 Concanavalin A Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000011535 reaction buffer Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 3
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- HUEYSSLYFJVUIS-MRFSYGAJSA-N (2s,3r,11bs)-2-[[(1r)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine;hydron;chloride Chemical compound Cl.N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC HUEYSSLYFJVUIS-MRFSYGAJSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100351314 Caenorhabditis elegans pdk-1 gene Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108050009160 DNA polymerase 1 Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229960001923 emetine hydrochloride Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KHLLRHIUKOJXLL-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride;hydron;chloride Chemical compound Cl.NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 KHLLRHIUKOJXLL-UHFFFAOYSA-N 0.000 description 1
- WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- HRTNVZOWEFVIGJ-UHFFFAOYSA-N 2-anilino-4h-1,3-thiazol-5-one Chemical class S1C(=O)CN=C1NC1=CC=CC=C1 HRTNVZOWEFVIGJ-UHFFFAOYSA-N 0.000 description 1
- UBYXITFNZVIVDW-UHFFFAOYSA-N 4-methylbenzenecarboximidamide Chemical class CC1=CC=C(C(N)=N)C=C1 UBYXITFNZVIVDW-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101900234631 Escherichia coli DNA polymerase I Proteins 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- -1 PRO nigeroline Chemical compound 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 229940123752 RNA synthesis inhibitor Drugs 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101800001530 Thymosin alpha Proteins 0.000 description 1
- 108091032917 Transfer-messenger RNA Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical class ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- OTCKNHQTLOBDDD-UHFFFAOYSA-K gold(3+);triacetate Chemical compound [Au+3].CC([O-])=O.CC([O-])=O.CC([O-])=O OTCKNHQTLOBDDD-UHFFFAOYSA-K 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- YXCDJKQYFBEAOU-UHFFFAOYSA-N phenyl thiocyanate Chemical compound N#CSC1=CC=CC=C1 YXCDJKQYFBEAOU-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000002262 tip cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は生理活性ポリペプチド更に詳しくはリンホトキ
シン活性を有する新規ポリペプチドに関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to physiologically active polypeptides, and more particularly to novel polypeptides having lymphotoxin activity.
リンホトキシン(以下LTと略)はリンパ球及びリンパ
球系株化細胞から特異的又は非特異的に放出される細胞
障害活性kmするリンホカインの1種として知られてい
る。LTは棟々の癌細胞に対して障害性があるばかりで
な(、ある種の抗癌剤又はインターフェロンの細lI′
C!1[杏効果を増強することから抗腫瘍剤として医薬
への応用が期待されている。〔グレンジャー(Gran
ger G、A、 )ら、第14回国際化学僚法学会、
京都、1985年6月23〜28日、アブストラクツ、
第15貞(International Congre
ss of Chemotherapy 。Lymphotoxin (hereinafter abbreviated as LT) is known as a type of lymphokine that is released either specifically or non-specifically from lymphocytes and lymphoid cell lines and has cytotoxic activity. LT is not only harmful to many cancer cells (such as certain anticancer drugs or interferon molecules)
C! 1 [Since it enhances the apricot effect, it is expected to be applied in medicine as an antitumor agent. [Gran
Ger G, A, et al., 14th International Chemical Law Society Conference,
Kyoto, June 23-28, 1985, Abstracts,
International Congress
ss of Chemotherapy.
Ky:+to、 Japan、 June 23−28
、 Abstractspl 5);ffツナガ(M
atsunaga K、 )ら、同上アブストラクツ、
第352頁〕
ヒト由来細胞によるLT産生については、扁桃細胞また
は末梢血リンパ球をフイトヘムアグルチニン(以下PH
Aと略)と共に培養し、その培養上清から取得する方法
〔ビータ−(Peter J、B、 )ら、ジャーナル
・オブ・イムノロジー(J。Ky:+to, Japan, June 23-28
, Abstractspl 5); ff Tsunaga (M
Atsunaga K, ) et al., Abstracts of the above,
[Page 352] Regarding LT production by human-derived cells, tonsil cells or peripheral blood lymphocytes were treated with phytohemagglutinin (hereinafter referred to as PH).
Method of culturing with A) and obtaining it from the culture supernatant [Peter J, B, et al., Journal of Immunology (J.
工nnmuno1.1)1 770 (1973) :
ウォーカーら(Walfer S、M、 and Lu
cas Z、J、 )、ジャーナル・オブ・イムノロジ
ー(J 、 ■mmunol、 1091233(19
72))、リンパ球系株化細胞をPMAの存在下に培養
し、その培養上清から取得する方法〔ヤマモト(Yam
amoto R,S、 )ら;ジャーナル・オブ・バイ
オロジカル・レスポンス・モデイファイアーズ(J、
Biol、 Re5ponse Modifiers)
3 76(1984))、ヒトT細胞ハイブリドーマを
ホルボールミリステートアセテート(以下PMAと略〕
及び/又はコンカナバリンA(以下Con Aと略)の
存在下に培養する方法〔浅田ら:セルラー・イムノロジ
ー(Ce1l Immunol−、77150<198
3)))等が知られている。Engineering nnmuno1.1) 1 770 (1973):
Walker et al. (Walfer S, M, and Lu
cas Z, J, ), Journal of Immunology (J, ■mmunol, 1091233 (19
72)), a method in which lymphoid cell lines are cultured in the presence of PMA and obtained from the culture supernatant [Yamamoto et al.
amoto R,S, ) et al; Journal of Biological Response Modifiers (J,
Biol, Re5ponse Modifiers)
3 76 (1984)), human T cell hybridomas were treated with phorbol myristate acetate (hereinafter abbreviated as PMA).
and/or a method of culturing in the presence of concanavalin A (hereinafter abbreviated as Con A) [Asada et al.: Cellular Immunol-, 77150<198
3))) etc. are known.
然し、これらの方法は、生麺量が少なく、又培地に高価
な栄養源(例えば牛胎児血清)を必要とする等LTを高
純度かつ経済的に取得することは非常に困難である。However, these methods require a small amount of raw noodles and require an expensive nutrient source (for example, fetal bovine serum) in the medium, making it extremely difficult to economically obtain LT with high purity.
LTi犬量に得るための他の方法として、いわゆる遺伝
子操作の手法を用い、LTに対応する遺伝子全ベクター
に組込み細菌、カビ、酵母又は動物赳胞内で複製、転写
、翻訳せしめてこれら細胞により生産させることが考え
られ、LTに対応する遺伝子の取得が待望されていた。Another method for obtaining large amounts of LTi is to use so-called genetic engineering techniques, in which the entire gene corresponding to LT is incorporated into a vector, replicated, transcribed, and translated in bacteria, fungi, yeast, or animal cells, and then transmitted by these cells. It has been considered that the gene corresponding to LT can be produced, and the acquisition of the gene corresponding to LT has been long awaited.
本発明者らは、先にエメチンーアクチノマイシンD法を
用い細胞融合を行いLTを産生するヒトT細胞ハイブリ
ドーマクローンA−C5−8株を取得した〔浅田ら;セ
ルラー・イムノロジー(cell、 Immunol、
77 150 (1983)J)。The present inventors previously obtained the human T cell hybridoma clone A-C5-8 strain that produces LT by cell fusion using the emetine-actinomycin D method [Asada et al.; Cellular Immunol.
77 150 (1983) J).
しかし、A−C5−8株’i< Con A %P)a
の存在下LT最適注生条件(培資時間30時間以上〕で
培養してもLTVこ対E’t、するメツセンジャーRN
A (以下mRNAとN)k取得できず、従ってLTに
対応する遺伝子も取得できなかった。However, A-C5-8 strain'i<Con A %P)a
Even if cultured under LT optimal injection conditions (culture time 30 hours or more) in the presence of
A (hereinafter referred to as mRNA and N)k could not be obtained, and therefore the gene corresponding to LT could not be obtained either.
そこで本発明者らはLTに対応するmRNAの取得条件
全独々検討した結果、A−C5−8株全PMA及び/又
はCon Aと共に24時間以内(特に4時間以内)培
養することにより、細胞内に生成したLTポリペプチド
に対応するmRNA f取得できることを見出し、更に
このmRNAよジ遺伝子組換え技術全応用することによ
り、LTポリペブチ更に、本発明者らは鋭意研究全1ね
た結果、(の訪)ヲ組込んだ形質発現ベクターで形質転
換された微生物中でLTポリペプチド全生産させること
に成功し、更にこのようにして生産されたヒトLTrl
?リペプチド含有生産物から、実質的に不純物ケ含まな
いヒトLTポリペプチド全得ることに成功し本発明全完
成した。Therefore, the present inventors independently investigated the conditions for obtaining mRNA corresponding to LT, and found that by culturing A-C5-8 strain with whole PMA and/or Con A within 24 hours (particularly within 4 hours), cells The present inventors have found that it is possible to obtain mRNA f corresponding to the LT polypeptide produced within the LT polypeptide, and by applying this mRNA and gene recombination technology, the present inventors have conducted extensive research and found that ( ) We succeeded in producing the entire LT polypeptide in a microorganism transformed with an expression vector that had been integrated into the human LTrl.
? The present invention has been completed by successfully obtaining the entire human LT polypeptide substantially free of impurities from the repeptide-containing product.
遺伝子組換え技術を用いてLT?!−生産する方法に関
し、グレイらの報告(P、W、 Gray et al
;Nature 312 721 (1984) )
がある。LT using genetic recombination technology? ! - Regarding the production method, report by Gray et al. (P, W, Gray et al.
; Nature 312 721 (1984))
There is.
Grayらは、ヒト末梢血リンパ球の非接着細胞をPM
A 、スタフイロコツカル エンテロトキシンB及びサ
イモシンα、と共に48時間培養後、細胞よりmRNA
を取得しcDNAを作成、制限酵素で切断後合成オリゴ
ヌクレオチドとライデージョン後、大腸菌内でLTi発
現させている。この報告から推定されるLTはアミノ酸
残基数171又は172、分子量I B、60 [1を
有する。Gray et al. PMed nonadherent human peripheral blood lymphocytes.
A, Staphylococcus mRNA was extracted from cells after 48 hours of culture with enterotoxin B and thymosin α.
After cDNA was obtained and cDNA was created, it was cut with a restriction enzyme, and after ligation with a synthetic oligonucleotide, LTi was expressed in E. coli. LT estimated from this report has a number of amino acid residues of 171 or 172 and a molecular weight of IB, 60[1].
本発明において、mRNAはヒト細胞ハイブリドーマよ
ジ取得していること、mRNAより誘導したcDNAの
塩基配列が異なることなどの相違がある他、本発明のL
TポリペブチVのアミノ酸残基数が152であジ分子量
が異なると共にアミノ酸配列でも7番目のアミノ酸が異
なる。In the present invention, the mRNA of the present invention has differences such as being obtained from human cell hybridomas and the base sequence of cDNA derived from the mRNA is different.
The number of amino acid residues of T polypeptide V is 152, the molecular weight is different, and the seventh amino acid in the amino acid sequence is different.
〔問題点を解決するための手段〕 ゛
即ち本発明はLT活性を有する新規なポリペプチドを提
供するものである。[Means for Solving the Problems] That is, the present invention provides a novel polypeptide having LT activity.
更に評しくは%願昭60−289249号明細書で得た
LTポリペプチドをコードするcDNA(第1表)を制
限酵素で切断し、別に翻訳開始部位全4人した形質発現
ベクターを同じ制限酵素で切断したものとを、ライプ−
ジョンしてLTポリペプチド生産用の形質発現ベクター
ケ得、この形質発現ベクターを適当な宿主例えば大腸菌
などに導入することにより形質転換体を得て、該形質転
換体全培養して得た培養物から抽出、精製して得た不純
物全実質的に含まないヒ)LTポリペプチドに関する。More specifically, the cDNA (Table 1) encoding the LT polypeptide obtained in Application No. 60-289249 was cut with restriction enzymes, and a gene expression vector with all four translation initiation sites was cut with the same restriction enzymes. Cut it with
A transformant is obtained by introducing the transformant into a suitable host such as E. coli, and the whole transformant is cultured. The present invention relates to a) LT polypeptide substantially free of all impurities obtained by extraction and purification.
以下全白
ヒ)LTポリペプチドは次式(1)のアミノ酸配列を有
する。The LT polypeptide has the amino acid sequence of the following formula (1).
以下余白
式(1)
%式%
上述のポリペプチド及び第1表の塩基配列中の符号は以
下の略号である。Below is the blank formula (1) % formula % The codes in the above-mentioned polypeptides and the base sequences in Table 1 are the following abbreviations.
ALA :アラニン、 ARC) :アルギニ
ン、ASN:アスパラギン、 ASP:アスパライ
ン酸、CYSニジスティン、 ()LN:グルタ
ミン、GLU:グルタミン酸、 GLYニゲリシン
、HIS:ヒスチジン、ILE:イソロイシン、LEU
:ロイシン、 LYS:リジン、MET :メ
チオニン、PHE :フェニルアラニン、PROニゲロ
リン、 SER:セリン、THR:スレオニ
ン、 TRP:)リプトファン、TYR:チロシ
ン、 VAL:バリン、A :アデニン、
C:シトシン、G ニゲアニン、 T
:チミン、尚、ヒトLT活性を有するポリペプチドのア
ミノ酸配列に関してはヒトリンパ芽球細胞株RPM1)
788由米の分子量20.000と25.000のLT
に関しアガワ# (B、B、 Aggarwal )ら
の報告〔デ・ジャーナル・オブ・バイオロジカル・ケミ
ストリー(J、 Biol、 Chem、、 260
2ろろ4(1985,1)があるが、本発明のポリペプ
チドとは上記アミノ酸配列中7番目のアミノ酸残基が異
なる。ALA: alanine, ARC): arginine, ASN: asparagine, ASP: asparaic acid, CYS nigistein, ()LN: glutamine, GLU: glutamic acid, GLY nigericine, HIS: histidine, ILE: isoleucine, LEU
: leucine, LYS: lysine, MET: methionine, PHE: phenylalanine, PRO nigeroline, SER: serine, THR: threonine, TRP:) liptophan, TYR: tyrosine, VAL: valine, A: adenine,
C: cytosine, G nigeanin, T
: Thymine; regarding the amino acid sequence of the polypeptide having human LT activity, refer to the human lymphoblastoid cell line RPM1)
LT of 788 Yumai molecular weight 20.000 and 25.000
A report by Aggarwal et al. [Journal of Biological Chemistry (J, Biol, Chem, 260)]
2 Roro 4 (1985, 1), which differs from the polypeptide of the present invention in the seventh amino acid residue in the above amino acid sequence.
さらに大腸菌で発現させる場合LTポリペプチド内に存
在するメチオニン残基金翻訳開始コドンとして用いるた
め余分なメチオニン残基の付加を防ぐことができる。Furthermore, when expressed in E. coli, the methionine residue present in the LT polypeptide is used as a translation initiation codon, so addition of an extra methionine residue can be prevented.
以下に不発EりJ’に詳a K説明する。The misfire will be explained in detail below.
■LT高産生産生細胞択 。■Selection of LT high-producing cells.
LT産生細胞としては、正常ヒトリンパ球、CCRF−
CEM 、 MOLT−AF %JURKAT等ヒト
Tリンパ球糸株化細廊及びそのクローニング株、RPM
I−1788等ヒ) B IJンパ球系株化細胞を用い
ることができるが、LT産生量が尚く細胞の継代が可能
であることから、正常ヒトでリンパ球とヒトTリンパ原
糸株化細胞とを細胞融合して得たLT産生ヒ)T細胞ハ
イブリドーマを用いることが好ましい。LT-producing cells include normal human lymphocytes, CCRF-
CEM, MOLT-AF %JURKAT, etc., human T lymphocyte cell lineage and its cloning strain, RPM
I-1788, etc.) B IJ lymphocyte lineage cell lines can be used, but since the amount of LT production is low and the cells can be passaged, normal human lymphocytes and human T lymphoid proteolytic cell lines can be used. It is preferable to use an LT-producing human T cell hybridoma obtained by cell fusion with human cells.
LTi生ヒ)T細胞ハイブリドーマは親細胞であるヒ)
T IJンバ球先糸株化細胞りLT産生fが筒く、従
って、細胞から抽出、分離されるmRBTAのtも多く
好適に用いられる。LTi live human) T cell hybridomas are the parental cells human)
The TIJ member's tip cell line produces LT, and therefore, the amount of mRBTA extracted and separated from the cells is also suitably used.
なお、LTの活性測定に用いた分析法は、小林(Kob
ayashi Y、 )らの方法〔ジャーナル・オブ・
イムノロジー(J、 ImmunoL ) 122 7
91(1979))’!r用いて行った。すなわち、細
胞培養上清又は細胞抽出物試料のマウスL・P3細胞(
L細胞の亜株)に対する障害活性全指標として測定した
。LTの1単位/1は、50%の標的細胞全障害する濃
度で表わした。The analytical method used to measure LT activity was that of Kobayashi (Kobashi).
ayashi Y.) et al. [Journal of
Immunology (J, ImmunoL) 122 7
91 (1979))'! This was done using r. That is, cell culture supernatant or cell extract sample of mouse L/P3 cells (
It was measured as a total indicator of damaging activity against L cell sub-strains). 1 unit/1 of LT was expressed as the concentration that caused total damage to 50% of the target cells.
LTi生ヒトT細胞ハイブリドーマは公知の方法(特開
昭58−72520号公報〕により製造することができ
る。LTi live human T cell hybridoma can be produced by a known method (Japanese Patent Application Laid-open No. 72520/1983).
すなわちヒ) T IJンパ球系腫瘍細胞を蛋白質合成
阻害剤又はこれとRNA合成阻害剤との併用により処理
し、ヒトTリンパ球全マイト−ジエン又は抗原で刺激し
、両者を融合促進剤(ポリエチレングリコール等)の存
在下で融合させ、得られた融合細胞(ヒトT細胞バイブ
IJ )F−マ〕だけを分離して取得することができる
。ヒト’r 、m胞ハイプリドーマ全培養液(例えは基
礎培地RPMニー1640培地に10%牛脂児血清、5
x10−5Mの2−ヌルカフ0トエタノール、2mMの
グルタミン全添加した培養液(以下、RPMI培地と略
〕中、37°C,Co25%−空気95%の雰囲気下で
培養し、前述のLT産生ヒ)T細胞ハイブリドーマ全ス
クリーニングする。In other words, T IJ lymphoid tumor cells are treated with a protein synthesis inhibitor or a combination thereof with an RNA synthesis inhibitor, stimulated with human T lymphocyte whole mitogen or antigen, and both are treated with a fusion promoter (polyethylene (glycol, etc.), and only the resulting fused cells (human T cells (Vibe IJ) F-ma) can be isolated and obtained. Human 'r, m cell hybridoma whole culture solution (for example, basal medium RPM Nee 1640 medium, 10% tallow serum, 5
Cultured at 37°C in an atmosphere of 25% Co-95% air in a culture medium (hereinafter referred to as RPMI medium) supplemented with 10-5M 2-nucleated ethanol and 2mM glutamine to produce LT as described above. h) Screen all T cell hybridomas.
■細胞培養
LTi生ヒトT細胞ハイブリドーマからmRNAを取得
するたぬには、最低10’個以上の細胞が必要であジ、
それらは細胞培養によって取得することが一般的である
。すなわち、細胞全栄養培地中105〜107個/ +
o’ K調製したものを、シャーレ、組織培養用フラス
コ回転培養液(スピナーフラスコ)内でC025%−空
気95チの雰囲気下、67°Cで培養する。■Cell culture To obtain mRNA from LTi live human T cell hybridomas, at least 10' cells are required.
They are commonly obtained by cell culture. i.e. 105-107 cells/+ in total cell nutrient medium
The o'K prepared product is cultured at 67°C in a Petri dish or tissue culture flask rotating culture solution (spinner flask) in an atmosphere of 25% CO-95% air.
培養時間は、培地、組成、初期細胞濃度によV異なるが
1〜5日間が適当である。培養液を遠心分離し細胞を取
得する。The culture time varies depending on the medium, composition, and initial cell concentration, but 1 to 5 days is appropriate. Centrifuge the culture solution to obtain cells.
栄養培地は、糖類、アミノ酸、ビタミン類、ホルモン類
、蛋白質、抗生物りよ、成長因子類及び刺機塩類等から
選ばれた一棟以上を含有する基礎培地、又は基礎培地に
動物血清を添加した培地から適宜選択して用いる。The nutrient medium is a basal medium containing one or more selected from saccharides, amino acids, vitamins, hormones, proteins, antibiotics, growth factors, and salts, or a basal medium to which animal serum is added. The appropriate medium is selected and used.
基礎培地としては、市販されているRPMI−1640
培地、MEM培地、ダルベツコ変法MEM培地等も使用
できる。As a basal medium, commercially available RPMI-1640
Medium, MEM medium, Dulbecco's modified MEM medium, etc. can also be used.
動物血清としては、牛胎児血清、新生牛血清、馬血清、
ヒト血清等全基礎培地に対し、1〜20チ添加すること
ができる。Animal serum includes fetal bovine serum, newborn bovine serum, horse serum,
1 to 20 units can be added to the total basal medium such as human serum.
又、細胞をヌードマウス、ハムスター等のヒト以外の温
血動物内で繁殖させて用いることもできる。The cells can also be propagated and used in warm-blooded animals other than humans, such as nude mice and hamsters.
0mRNAの増幅
■で取得したLT産生ヒ)T細胞ノ・イブリドーマを栄
養培地中10”〜10フ酎に調整し、史に丹植及び/又
はCon A k加えて培養することにより、LTに対
応するmRNAを多J1°に含むノI′(fl胞を取得
することができる。P彫・の好適濃度は20〜200
ng (ナノグラム) / tni%Con Aの好適
一度は5〜50μm1 / meの範囲である。LT-producing human T cell hybridoma obtained by amplification of 0mRNA is adjusted to 10" to 10" in a nutrient medium and cultured by adding Tanshu and/or Con A k to LT. It is possible to obtain NoI'(fl cells) containing mRNA in the J1°.
The preferred range of ng (nanograms)/tni% Con A is 5-50 μm/me.
培養時間は24時間以内特に8時間以内が適当である。The culture time is suitably within 24 hours, especially within 8 hours.
その理由μ、培−aaat+胞のリンホトキシン活性に
対応するmRNAの含量が、時間の経過と共に減少する
からである。特に24時間を超える場合、LT産生ヒ)
T細胞ハイブリドーマ全培養し、培重上清からLTを回
収するための最適時間24〜72時間では細胞内のLT
に対応するmRNAかは極めて微は゛でありm朋A全回
収することは困難である。The reason for this is that the content of mRNA corresponding to lymphotoxin activity in μ, medium-aaat+ cells decreases with the passage of time. Especially if it exceeds 24 hours, LT production
The optimal time for culturing T cell hybridomas and collecting LT from the culture supernatant is 24 to 72 hours, when intracellular LT
The amount of mRNA corresponding to this is extremely small, and it is difficult to recover all of it.
■細胞より全RNAの抽出
■で取得した細胞から全RNAの抽出は塩酸グアニジン
法〔ディージ−(Deeley F、、G、 )ら、デ
・ジャーナル・オブ・バイオロジカル・ケミストリー(
J、 Biol、 Chem、 ) 252 8310
(1977))等公知の方法で実施できる。■ Extraction of total RNA from cells Extraction of total RNA from the cells obtained in step (■) was performed using the guanidine hydrochloride method [Deeley F, G, et al., Journal of Biological Chemistry (
J, Biol, Chem, ) 252 8310
(1977)) and other known methods.
−jなわち、■で取得した細胞(109個以上)を、ホ
モジネート緩衝′g!1.(8M塩酸グアニジン、51
)nMジチオスレイトール、20mM酢酸ナトリウム含
有、 NaOHでp)17に調整)に懸濁し、ホモジ
ナイヂー等で破壊する。破縫物よジェタノール沈殿、フ
ェノール抽出により全核酸全抽出後、塩化リチウム沈殿
によジ全RNA i回収する。抽出操作はRNaseに
よるRNAの分解を防ぐため、器具は乾熱又はジエチル
ピロカーボネート処理後オートクレーブ滅菌し、操作中
はビニル手袋を看用することが好ましい。-j That is, the cells (109 or more) obtained in ■ are homogenate buffered! 1. (8M guanidine hydrochloride, 51
) containing nM dithiothreitol and 20 mM sodium acetate, adjusted to p)17 with NaOH, and disrupted by homogenization. After extracting all the nucleic acids from the broken tissue by geltanol precipitation and phenol extraction, the total RNA is recovered by lithium chloride precipitation. In order to prevent degradation of RNA by RNase during the extraction operation, it is preferable to sterilize the equipment in an autoclave after treatment with dry heat or diethylpyrocarbonate, and to wear vinyl gloves during the operation.
■全RNAよF) mRNAの分離
全RNAから目的とするmRNAの分離は、ショ糖密度
勾配遠心法、ケ゛ル濾過法、電気泳動による方法、メン
ブランフィルタ−法、オリゴdTカラムを用いる方法等
公知の方法、又はこれらを組合わせることによって実施
できる。■Total RNA (F) Separation of mRNA The desired mRNA can be separated from total RNA using known methods such as sucrose density gradient centrifugation, gel filtration, electrophoresis, membrane filtering, and methods using oligo dT columns. It can be carried out by any method or by a combination of these methods.
ここに得られたmRNAが目的とするLT iコードす
るものであることを確認するためには、m態へを蛋白質
に翻訳させてその生物活性を調べれはよい。例えばアフ
リカッメガエル〔ゼノパス・レビス(Xenopus
1aevis ) )の卵母細胞、網状赤血球ライゼー
ト、小麦胚芽のような適当な蛋白合成糸にmRNA 全
注入又は添加して蛋白質に翻訳させ、その蛋白質がマウ
スL−P3細胞に対して細&!i障害活性を示すことを
確認することにより行われる。In order to confirm that the obtained mRNA encodes the desired LTi, it is recommended to translate the protein into the m-state and examine its biological activity. For example, the African frog (Xenopus levis)
1aevis))), reticulocyte lysate, or wheat germ, the whole mRNA is injected or added to a suitable protein synthesis thread, and the protein is translated into protein. This is done by confirming that the test shows i-damaging activity.
尚、アフリカッメガエルの卵母細胞を用いる方法は例え
ば次のようにして行なわれる。The method using African frog oocytes is carried out, for example, as follows.
卵母細胞1個当り約50〜1)00nのmRNA fマ
イクロインジェクション法で注入し、その20個全モデ
ィファイド・パース・ソルト液(1lodi−fied
Barth 5alt 5olution ) (N
aCtO,13& 5KC10,075& %NaHC
O30,22%MgSO4・7H200,2,!?、C
a(Noz)2・4H200,(38/l % CaC
42・6H200,09g、HEPES 2.38 、
!9、ストレプトマイシン100.9.ペニシリンG(
10万単位)を1tに溶解;阻7.4、以下MBSと略
))200μを中26°Cで48時間培養する。この培
養上清を試料として、L−、P3細胞障害活性を指標と
してLT活性を測定1゛る。Approximately 50 to 1)00 n of mRNA per oocyte was injected using the f microinjection method, and 20 of them were injected in total modified Perth salt solution (1 lodi-fied).
Barth 5alt 5solution ) (N
aCtO,13&5KC10,075&%NaHC
O30,22%MgSO4・7H200,2,! ? , C
a(Noz)2・4H200, (38/l % CaC
42.6H200.09g, HEPES 2.38,
! 9. Streptomycin 100.9. Penicillin G (
Dissolve 100,000 units) in 1t; Using this culture supernatant as a sample, LT activity is measured using L- and P3 cytotoxic activity as an indicator.
と
本発明のLT畜コードするmRNAは次の性質により#
徴つけられる。The mRNA encoding the LT animal of the present invention has the following properties.
be arrested.
■12.6 S〜14.68のS甑を有する。■It has an S capacity of 12.6 S to 14.68.
■3′ 末端にポリアデニル′酸桐造を有する。■Has polyadenylic acid Kirizo at the 3' end.
■LTのポリペノチドケコードする。■ LT polypenotide code.
■リンホトキシンcDNAのクローニング■の操作で得
られたmRNAを鋳型とし、オリゴ(dT )をプライ
マーとして、(iATP、 dGTP。■ Cloning of lymphotoxin cDNA Using the mRNA obtained in step (■) as a template and using oligo (dT) as a primer, (iATP, dGTP).
dCTP% dTTPの存在下で逆転写酵素(例えばト
リ骨髄性白血病ウィルス由来逆転写酵素〕によりmRN
Aと相補的な単鎖cDNA f合成し、熱処理で鋳型m
RNA k変性させる。次いで、この単鎖cDNAを鋳
型にして、大腸菌DNAポリメラーゼI(クレノウフラ
グメント〕?用いて二重鎖DNA 1.f合成する。dCTP% mRNA is produced by reverse transcriptase (e.g. avian myeloid leukemia virus reverse transcriptase) in the presence of dTTP.
Single-stranded cDNA f complementary to A is synthesized and heat-treated to create template m.
Denature RNA. Next, using this single-stranded cDNA as a template, double-stranded DNA 1.f is synthesized using Escherichia coli DNA polymerase I (Klenow fragment).
この二重鎖DNA ’にアルカリ処理及びフェノール抽
出?行い、変性mRNA及び蛋白から分離する。この二
重鎖DNAに逆転写酵素全作用させ、さらに完全な二重
鎖DNAを合成する。ここに得られたDNAはヘアピン
栴造會有するのでSエヌクレアーゼ〔アスペルギルス・
オリーゼ(Aspergillusoryzae )
:米麹因由米S1ヌクレアーゼ〕によりヘアピン構造を
切断し、完全な二重鎖構造のDNAt得る。ここで得ら
れたDNA ’iポリ(dG)−ポリ(dC)又はポリ
(dAJ−ポリ(dT)ホモポリマー伸長法〔ノダ(N
oda M、 )ら、ネイチャー(Nazure)29
5 202(1982);マニアチス(Mani−at
is T、 )ら、「モレキュラー・クローニング(ア
・ライラリー・マニュアル) J ”Molecula
rcxoning(a 1aboratory man
ual )217(1982)コールド・スプリング・
ノ・−バー・ラボラトリ−(Co1d Spring
Harbor Laboratory)ニューヨーク〕
のような常法に従って、例えばプラスミドpBR322
の制限酵素Pst I切断部位に組み込ませる。得られ
た組換えプラスミドを、例えはペルパル(Perbal
B、 )の「ア・シラクチカル・ガイド・トウ・モレ
キュラー・クローニング」”A Practical
Guide to Mo1ecu1ar Clonin
g″268(1984)、ジョン・ウィリー・アンド・
サン101株のような宿主に尋人して形但転換させ、テ
トラサイクリン耐性株全選択してc DNAライブラリ
ーを作製する。Alkali treatment and phenol extraction on this double-stranded DNA? and separate it from denatured mRNA and protein. This double-stranded DNA is subjected to full action of reverse transcriptase to further synthesize complete double-stranded DNA. Since the DNA obtained here has a hairpin structure, S enclease [Aspergillus
Aspergillus oryzae
The hairpin structure is cleaved using rice malt and rice S1 nuclease to obtain DNAt with a complete double-stranded structure. The DNA obtained here was obtained using the poly(dG)-poly(dC) or poly(dAJ-poly(dT) homopolymer elongation method [Noda(N
oda M, ) et al., Nature 29
5 202 (1982); Maniatis (Mani-at
is T, et al., “Molecular Cloning (A Library Manual) J”Molecular
rcxoning (a 1 laboratory man
ual ) 217 (1982) Cold Spring
Nova Laboratory (Co1d Spring
Harbor Laboratory) New York]
For example, plasmid pBR322
into the restriction enzyme Pst I cleavage site. The obtained recombinant plasmid, for example, Perbal
"A Practical Guide to Molecular Cloning" by B.)
Guide to Mo1ecu1ar Clonin
g″268 (1984), John Wiley &
A host such as the Sun 101 strain is transformed, and all tetracycline-resistant strains are selected to create a cDNA library.
このcDNAライブラリーについて合成プローブ全利用
したコロニー・ノ−イブリダイゼーション試験〔モント
ゴメリ−(Montgomery D、L、 )ら、セ
ル(Cel’1)14 673(1978);rデル(
Goeddel、 D、V、 )ら、ニュークレイツク
・アシツズ・リサーチ(Nucleic Ac1ds
Res、 ) 84057(1980))により目的の
クローンをスクリーニングする。即ち、グレイらがネイ
チャー (Nature ) 312 721 (19
84)に報告しているリンホトキシンの404から42
1香目の18塩基並びに500から517番目の18塩
基に対応する相補的な塩基配列を化学合成し、ポリヌク
レオチドキナーゼ(T4ファージが感染した大腸菌白米
T4ポリヌクレオチドキナーゼ〕でプローブの5′末端
の水酸基にγ−”2P−ATPのリン酸を転移させ、3
2P:標識した2a[のプローブ全作製する。前述のC
DNAライブラリーの中から両プローブに強く結合する
クローン’kA択する。Colony no-bridization tests using all synthetic probes for this cDNA library [Montgomery D, L, et al., Cel'1 14 673 (1978);
Goeddel, D.V., et al., Nucleic Acids Research.
Res, ) 84057 (1980)) to screen the clone of interest. That is, Gray et al. Nature 312 721 (19
404 to 42 of lymphotoxin reported in 84)
A complementary base sequence corresponding to the 18 bases of the first aroma and the 18 bases from 500 to 517 was chemically synthesized, and the 5' end of the probe was synthesized using polynucleotide kinase (Escherichia coli white rice T4 polynucleotide kinase infected with T4 phage). Transferring the phosphoric acid of γ-”2P-ATP to the hydroxyl group, 3
2P: Prepare all labeled 2a probes. The above C
A clone 'kA that strongly binds to both probes is selected from the DNA library.
ここで得られたクローンからプラスミv DNA を分
離し、加熱又はアルカリ変性により単鎖DNAとしニト
ロセルロースフィルターに固定する。これにリンホトキ
シンmRNA k 宮むmRNA画分を加えハイブリダ
イズさせた後、結合したmRNA f溶出回収し、これ
をアフリカッメガエルの卵母細胞に注入し、回収された
mRNAがリンホトキシンをコードしているか否かを検
討する(以下、〕・イブリダイゼーション・トランスレ
ーション試験といつ)。Plasmi v DNA is isolated from the clones obtained here, and fixed to a nitrocellulose filter as single-stranded DNA by heating or alkaline denaturation. Lymphotoxin mRNA k Miyamu mRNA fraction was added to this and hybridized, and the bound mRNA f was eluted and recovered. This was injected into African frog oocytes, and the recovered mRNA encoded lymphotoxin. (hereinafter referred to as "Ibridization/Translation testing" and "When").
以上の方法によりリンホトキシンのmRNAと相補性の
ある塩基配列を含むDNA断片を組込んだクローン化D
NA i得ることができる。Cloned D into which a DNA fragment containing a base sequence complementary to lymphotoxin mRNA was incorporated by the above method.
NA i can be obtained.
丈に、この形質転換株のクローン化DNA断片を適尚な
制限酵素で切出し、32pで標識したもの全ゾロープと
して用い、前述のcDNAライブラIJ−全再スクリー
ニングすることにより、より大きなサイズのcDNA断
片を選択してもよい。The cloned DNA fragment of this transformed strain was excised with an appropriate restriction enzyme, labeled with 32p, and used as a total zorope, and rescreened with the aforementioned cDNA library IJ to obtain a larger size cDNA fragment. may be selected.
このようにして得られた、クローン化DNA断片につい
て、制限酵素地図全作製し、M13ファージによりクロ
ーニングし、サンガー(Sanger F、)ら〔プロ
シーディンゲス・オブ・デ・ナショナル・アカデミ−・
オプ・サイアンシーズ・オブ・デー U S A (P
roc、 Natl Acad、 Sci、 USA
) 745463(1977))のジデオキシシーフェ
ンス法に従って塩基配列全解析し、既に明らかになって
いるリンホトキシンのアミノ酸配列’tコ一にひ出すこ
とにより、リンホトキシンのアミノ酸配列を含むポリペ
プチドをコードする塩基配列を有するクローン化DNA
i得ることができる。For the thus obtained cloned DNA fragments, a complete restriction enzyme map was prepared and cloned using M13 phage, as described by Sanger F. et al. [Proceedings of the National Academy of Sciences].
Op Science of Day USA (P
roc, Natl Acad, Sci, USA
745463 (1977)), and by extracting the already known amino acid sequence of lymphotoxin, the base encoding a polypeptide containing the amino acid sequence of lymphotoxin was obtained. Cloned DNA with sequence
i can get it.
■LTポリペゾチドのアミノ酸配列をコードする塩基配
列を含む発埃ベクターの調製
■LTポリペゾチドのアミノ酸配列をコードするcDN
Aの制限酵素による切断
本発明のアミノ酸配列をコードするDNAの作製のため
には第1表に示す全cDNA f制限酵素N5ilc
DNA断片を抽出し、回収する。このcDNA断片は第
1表に示す全cDNAの225査目から840査目まで
を含む。■Preparation of dust vector containing the base sequence encoding the amino acid sequence of LT polypezotide ■cDNA encoding the amino acid sequence of LT polypezotide
Cleavage of A with a restriction enzyme For the production of DNA encoding the amino acid sequence of the present invention, all cDNA shown in Table 1.
Extract and collect DNA fragments. This cDNA fragment includes the entire cDNA shown in Table 1 from position 225 to position 840.
@合成オリゴヌクレオチドとL’I’ cDNA断片の
ライゲーシヨン
下記構造の合成オリゴヌクレオチド
AATTCTAT()CA
AT
た後、EcoR[で消化し常法に従って623 bpの
EcoR[断片を回収する。Ligation of synthetic oligonucleotide and L'I' cDNA fragment A synthetic oligonucleotide having the following structure AATTCTAT() CA AT is then digested with EcoR and a 623 bp EcoR fragment is recovered according to a conventional method.
○LT cDNA断片の発埃ベクターへの尋人発現ベク
ターpKK 223−3 (ファルマシア社製) ’k
EcoR[で消化した後、ウシ腸粘膜由来アルカリフ
ォスファターゼで5′末端の脱リン酸化を行う。0で作
成したEcoRI断片と上記の開環ベクターのライゲー
シヨンを行う。反応後閉環したベクターを常法に従って
回収し、大腸菌に形質転換する。○Translation of LT cDNA fragment into dust vector Hijin expression vector pKK 223-3 (manufactured by Pharmacia) 'k
After digestion with EcoR, the 5' end is dephosphorylated with alkaline phosphatase derived from bovine intestinal mucosa. Ligation of the EcoRI fragment created in step 0 and the above circular open vector is performed. After the reaction, the closed vector is recovered according to a conventional method and transformed into E. coli.
■合成オリゴヌクレオチドプローブによるスクリーニン
グ
■に示した32p標識した合成オリゴヌクレオチドプロ
ーブとθで作製した大腸菌の形質転換株とをコロニーハ
イブリダイゼーションし、合成オリゴヌクレオチドプロ
ーブとハイブリダイズする菌株全選択する。次いでこの
コロニーからベクターを調製し、制限酵素により切断後
アガロ−スケ”ルミ気泳動法によジ目的とする6 23
bpのcDNA断片を含むベクター全取得する。(2) Screening with synthetic oligonucleotide probes Colony hybridization is performed between the 32p-labeled synthetic oligonucleotide probe shown in (2) and the transformed strain of E. coli prepared in θ, and all strains that hybridize with the synthetic oligonucleotide probe are selected. Next, a vector is prepared from this colony, cut with a restriction enzyme, and subjected to agarose scale electrophoresis623.
Obtain the entire vector containing the bp cDNA fragment.
■LT cDNAの6′宋端非コード領域の除去■で取
得したベクター2 Hinamで直鎖状DNAにした後
、BAL 31ヌクレアーゼでLT cDNAの6′末
端非コード領域を除去する。次にDNAポリメラーゼ1
(フレノウフラグメント〕で末端ヶ平滑床端とした後E
coRIで消化し、ポリアクリルアミドグル電気泳動で
分画し、約4 ’60 bpの断片を回収する。(2) Removal of the 6' Song end non-coding region of the LT cDNA After converting the vector obtained in step (2) into a linear DNA using Hinam, the 6' end non-coding region of the LT cDNA was removed using BAL 31 nuclease. Next, DNA polymerase 1
After making the end smooth with (Flenow Fragment), E
It is digested with coRI and fractionated by polyacrylamide gel electrophoresis to recover a fragment of about 4'60 bp.
@ LT CDNAとリンカ−とのライダ1−ジョン■
で得た4 60 bp断片にHindl Linker
(全酒造製)七うイr−ジョンした後Hindlで消
化する。@LT Rider 1 John with CDNA and linker ■
Hindl Linker to the 460 bp fragment obtained in
(Manufactured by Zenshuzo Co., Ltd.) After seven irradiations, it was digested with Hindl.
θLT cDNAと発現ベクターとのライダ1−ジョン
pKK 223−3 k EcoRI MひにHind
lで消化し、4555 bpの断片を得る。次に@で得
た約465bp EcoRl −Hindu断片と結合
させ、常法により大腸菌に形質転換し、約A 65 b
p LT cDNA断片を有するベクターを取得する。Lidar 1-John pKK 223-3 k EcoRI M Hini Hind with θLT cDNA and expression vector
A fragment of 4555 bp is obtained. Next, it was ligated with the approximately 465 bp EcoRl-Hindu fragment obtained in
A vector containing the pLT cDNA fragment is obtained.
■多コピー発現ベクターの作成
pAT 153 (アマジャム社製) f Baz H
1並ひにPvu 1で消化し、アガロースゲル電気泳動
で分画し2655 bpの断片全取得する。一方■で得
たベクターもBam HI並ひPvu Iで消化し、同
様に約980 bpの断片全取得する。上記2櫨類のB
am Hニー Pvu I断片全ライプ−ジョンし、L
TcDNA断片を有するベクターを取得する。■Creation of multi-copy expression vector pAT 153 (manufactured by Amajam) f Baz H
Digested with Pvu 1 and fractionated by agarose gel electrophoresis to obtain all 2655 bp fragments. On the other hand, the vector obtained in step (3) is also digested with Bam HI and Pvu I, and the entire fragment of approximately 980 bp is obtained in the same manner. B of the above two oak species
Am H knee Pvu I fragment was completely replicated and L
A vector containing a TcDNA fragment is obtained.
@) LT cDNAの大腸菌内における発現■で取得
した大腸菌の形質転換体をイソプロピル−β−D−チオ
ガラクトシド(以下工PTC)と略)を含む培地中でO
D 550 nmが約1になるまで培養する。@) Expression of LT cDNA in E. coli The E. coli transformant obtained in step ① was incubated with O in a medium containing isopropyl-β-D-thiogalactoside (hereinafter abbreviated as PTC).
Culture until D 550 nm is approximately 1.
集凶後、超音波処理で菌体を破砕、トリス塩酸緩′#I
液(pH8,0)で抽出、無菌濾過後LT活性全測定し
最もLTポリペプチド発現分の多い形質転換体をスクリ
ーニングする。After collection, the bacterial cells are crushed by ultrasonication, and treated with Tris-hydrochloric acid (#I).
After extraction with a solution (pH 8, 0) and sterile filtration, total LT activity is measured and the transformant expressing the highest amount of LT polypeptide is screened.
■LTポリペプチド産生大腸菌の培養及び精↓■で取得
した形質転換体(LT産生大腸菌)をIPT() ’i
i含む培地中でLTポリペゾチドが十分に産生きれるま
で培養する。次いで培養物’k IJゾチーム消化と凍
結融解、超音波破砕、フレンチプレス、ダイノーミルな
どにより破砕した後遠心分離又は誰過により抽出液を集
める。この抽出液を硫安塩析、限外濾過、イオン交換ク
ロマトグラフィー、疎水クロマトグラフィー、ケ9ル濾
過、5DS−ポリアクリルアミドを気泳動等の組合せに
より精製しLTポリペプチドを実質的に純品として得る
ことができる。■Culture and purification of LT polypeptide-producing E. coli (LT-producing E. coli) by IPT()'i
Culture in a medium containing i until LT polypezotide can be sufficiently produced. Next, the culture is digested with 'k IJ zozyme and disrupted by freeze-thawing, ultrasonic disruption, French press, Dynomill, etc., and then the extract is collected by centrifugation or filtering. This extract is purified by a combination of ammonium sulfate salting out, ultrafiltration, ion exchange chromatography, hydrophobic chromatography, gel filtration, and 5DS-polyacrylamide gas phoresis to obtain the LT polypeptide as a substantially pure product. be able to.
■[相]で得たLTポリペプチドに関し、アミノ酸組成
及びN末端アミノ酸配列を測定した結果、実施例に示す
ように式([)から推定される値と一致した。(2) Regarding the LT polypeptide obtained in [phase], the amino acid composition and N-terminal amino acid sequence were measured, and as shown in the Examples, the results matched the values estimated from the formula ([).
以下実施例を挙げて本発明を更に具体的に説明するが本
発明はこれら実施例に限定されるものではない。The present invention will be described in more detail below with reference to Examples, but the present invention is not limited to these Examples.
実施例1
(1)リンホトキシン産生ヒトT細胞ノ飄イプリドーマ
の調製
ヒト末梢血リンパ球(以下PBLと略)106個/ 祷
’i ’M’MI培地中、コンカナバリンA(以下Co
n Aと略)20μ:i/mにより2日間処理後、0.
2Mのα−メチル−D−マンノシドにて細胞に結合した
Con A f可及的に除去した。Example 1 (1) Preparation of lymphotoxin-producing human T cell ipridoma 106 human peripheral blood lymphocytes (hereinafter referred to as PBL)/concanavalin A (hereinafter referred to as Co
abbreviated as n A) 20μ: After treatment with i/m for 2 days, 0.
Con Af bound to the cells was removed as much as possible with 2M α-methyl-D-mannoside.
他方、RPMT培地中で増殖期にあるヒ) T IJン
パ球系)膿瘍細胞CCRF −CEM (以下CEMと
略〕を遠心分離で回収し、RPMI 164.0−10
mM HEPES培地中に2X10’個/WLlに懸
濁し、エメチン塩酸塩(半井化学社)及びアクテノマイ
シンD(PLバイオケミカルズ社)をそれぞれ5 X
10−5M及び0.25 p9 / rugとなるよう
に添加し、37°C12時間処理した後、培養液中のエ
メチン塩酸塩及びアクチノマイシンDi遠心除去した。On the other hand, human CCRF-CEM (hereinafter abbreviated as CEM) abscess cells in the proliferation phase in RPMT medium were collected by centrifugation, and RPMI 164.0-10
Emetine hydrochloride (Hani Kagaku Co., Ltd.) and actenomycin D (PL Biochemicals Co., Ltd.) were each suspended at 2X10' cells/WLl in mM HEPES medium at 5X.
After adding 10-5 M and 0.25 p9/rug and treating at 37°C for 12 hours, emetine hydrochloride and actinomycin Di in the culture solution were removed by centrifugation.
以上のように調製したPBLとCEM’a:10:1の
割合で混合後、遠心分離して得た細胞ベレットに0.5
扉g LD 46%示リすチレングリコール(PEG
−1540、和光純薬社〕、5μ9 / trtlの
ポリ−L−アルギニン及び15%ジメチルスルホキシド
含南MgM培地を加え、67°0145秒間ゆっくり攪
拌して融合させ、101!Llの25 mM HEPE
S (PH7,2)で緩衝化したMEM培地10罰をゆ
つくジ添加し、遠心した。After mixing PBL prepared as above and CEM'a at a ratio of 10:1, centrifugation was performed to obtain a cell pellet with 0.5
Door g LD 46% tyrene glycol (PEG
-1540, Wako Pure Chemical Industries, Ltd.], 5μ9/trtl of poly-L-arginine and Southern MgM medium containing 15% dimethyl sulfoxide were added, and the mixture was stirred slowly for 67°0145 seconds to fuse. 25 mM HEPE in Ll
Ten volumes of MEM medium buffered with S (PH 7,2) were slowly added and centrifuged.
細胞ペレットにRPMI培地を加え、細胞数を106個
/―とし、その100μtとフィーダー・セル(fee
der ceFl )としてマイトマイシンC処理した
OEM (4x 105個/ytl)含有RPMI培地
100μtとを混合し、96穴カルチヤープレートに加
え、CO25%−空気95%の雰囲気下、67°Cで約
3〜4週間培養後、増殖した融合細胞全上記マイトマイ
シンC処理CEM iフィーダー・セルとして限界稀釈
法によりクローン化し、各クローンの増殖後、リンホト
キシン活性の測定を行った。Add RPMI medium to the cell pellet to bring the number of cells to 106/-, and add 100 μt of the cell pellet and feeder cells (fee
der ceFl) was mixed with 100 μt of RPMI medium containing mitomycin C-treated OEM (4 x 10 cells/ytl), added to a 96-well culture plate, and incubated at 67°C for about 3 to 3 hours in an atmosphere of 25% CO and 95% air. After 4 weeks of culture, all of the proliferated fused cells were cloned as mitomycin C-treated CEM i feeder cells by the limiting dilution method, and after proliferating each clone, lymphotoxin activity was measured.
なお、培養条件については特に限らない限り、C025
%−空気95俤の雰囲気下、67°Cで行った。In addition, unless otherwise specified, the culture conditions are C025
%-Carried out at 67°C in an atmosphere of 95 air.
本発明に用いるリンホトキシン産生クローン化ヒトT細
胞ハイブリドーマA−05−8株金、2.5 X 10
5個/罰の細胞濃度でCan A 20 μj! /罰
及びPMA 20 ng /罰で刺激し、゛24時間培
養して得たリンホトキシン活性は250単位/罰であっ
た。他方未刺激のA−05−8株のリンホトキシン活性
は4.0単位/ meであった。Lymphotoxin-producing cloned human T cell hybridoma strain A-05-8 used in the present invention Gold, 2.5 x 10
Can A 20 μj at a cell concentration of 5 cells/punishment! The lymphotoxin activity obtained by stimulation with 20 ng/punishment and PMA 20 ng/punishment and culturing for 24 hours was 250 units/punishment. On the other hand, the lymphotoxin activity of the unstimulated A-05-8 strain was 4.0 units/me.
実施例2
(1)リンホトキシン産生ヒトT細胞ハイブリドーマ(
*−05−8)の培養
A−05−3株を5X1Q6〜107個/罰の細胞濃度
で、PMA及びCon A kそれぞれ終濃度10口n
g/ rttl s 20 μg/ rIteで添加し
て2,4.8゜24.48時間培養した。Example 2 (1) Lymphotoxin-producing human T cell hybridoma (
*-05-8) culture A-05-3 strain at a cell concentration of 5 x 1 Q6 ~ 107 cells/particle, PMA and Con A k each at a final concentration of 10 n
g/rttls was added at 20 μg/rIte and cultured at 2.4.8° for 24.48 hours.
(2)全RNAの調製
A−C5−8株の全RNA ’i油抽出る方法は主に塩
醗グアニジン法で行った。すなわち、実施例2−(1)
の各々の培養時間後のA−C5−8細胞を1)00Or
p、5分間遠心して集め、PBS (5mMのリン酸緩
衝液、0.15MのNaCt含有、p)i 7.4)に
懸濁した後、更に1000 rpmで5分間遠心して細
胞を洗浄した。(2) Preparation of total RNA Total RNA of strain A-C5-8 was extracted mainly by the salt-guanidine method. That is, Example 2-(1)
A-C5-8 cells after each culture time of 1) 00 Or
The cells were collected by centrifugation for 5 minutes, suspended in PBS (5 mM phosphate buffer, containing 0.15 M NaCt, p)i 7.4), and further centrifuged at 1000 rpm for 5 minutes to wash the cells.
この細胞〔実施例2− (1)の各々の培養時間でそれ
ぞれ4X108.6×108.3.2 X 10B 、
1.8×109及び2X109)t−ホモジネート緩衝
液に懸濁し、ホモジナイズした。このホモジネートに0
.025等量の1M酢酸及び1.5倍量の冷エタノール
(−20°C)を加え混合後、−20°Cに6時間以上
放置した。これを−10°Cで1500Orpm (R
PR18−20−ター、日立製作所要〕で30分遠心分
離し、生じた沈殿にウオツシング繍衝液(ホモジネート
緩衝液に2 [1nMEDTシ;を更に営々しているも
の、以下刀と略)ヲ加えてピペッティングで均一に溶解
後1M酢酸金加えてpH5とし、更に冷エタノールヲ1
.5倍針加え、−20°Cに6時間以上放置した。これ
を−10°Cで1500Orpmで30分間遠心分離し
、沈殿をwBに溶解、1M酢酸によるPH調整、冷エタ
ノール沈殿76回繰返した。This cell [Example 2-4 x 108.6 x 108.3.2 x 10B for each culture time of (1),
1.8×109 and 2×109) were suspended in t-homogenate buffer and homogenized. 0 for this homogenate
.. After adding and mixing 025 equivalent of 1M acetic acid and 1.5 times the amount of cold ethanol (-20°C), the mixture was left at -20°C for more than 6 hours. This was heated to -10°C and 1500Orpm (R
Centrifuge for 30 minutes using a PR18-20-ter, manufactured by Hitachi, Ltd., and add a washing buffer (in which 2 [1 nMEDT] is further added to the homogenate buffer, hereinafter abbreviated as sword) to the resulting precipitate. After dissolving it uniformly by pipetting, add 1M gold acetate to adjust the pH to 5, and add 1 liter of cold ethanol.
.. A 5x needle was added and the mixture was left at -20°C for more than 6 hours. This was centrifuged at -10°C and 1500 rpm for 30 minutes, and the precipitate was dissolved in wB, pH adjusted with 1M acetic acid, and cold ethanol precipitation was repeated 76 times.
エタノール沈殿物に少量の0.1%SDS ’i加えて
懸濁し、等量のエクストラクション緩衝液(0,5%S
DS 、 0.1 M NaCt、 50 mM酢
酸ナトリウム、5 mM EDTA 2Na含有、2日
5.2)と2等量の水飽和フェノール〔0,1%8−キ
ノリツール含有、100蜆トリス塩酸緩衝液(p)18
.0 )飽和〕−クロロホルムーイソアミルアルコール
溶液(体積比50:50:1)を加え、10分間振盪し
た後、6000rpm、10分間遠心分離した。三層に
分離した下層を除去し、上層と中間油に等量のクロロホ
ルム−イソアミルアルコール溶液(体積比50:1)を
加え、10分間振盪した後、3000 rpmで10分
間遠心分離し、下層全除去した。このクロロホルL−イ
ソアミルアルコール溶液による抽出操作を三回繰返した
。DNA% RNA 、糖等を含む上層に6M酢酸ナト
リウム(pH5,2)ko、1等量加え、2部付の冷エ
タノールを加え一20°Cで6時間以上放置後、150
00 rpm (RPR18−20−ター)で60分間
遠心分離した。生じた沈殿に少量の政凶蒸留水ケ加えて
ギ?解した後、等量の冷4M塩化リチウムを加え% 0
°Cに一夜放置し、15000 rpmで30分間遠心
分離し、沈殿を少量の2M塩化リチウムで洗浄後、滅菌
蒸留水を加えて溶解し、1/108の6M酢酸ナトリウ
ム(pH5,2) k加えた後、2等量の冷エタノール
を加え、−20°Cで3時間以上放置した。15000
rpmで30分間遠心分離し、沈殿’to、o I
M ) IJメス酸緩衝液(0,5M NaCL、
0.1%SDS 、 1mM EDTA3Na含有、
pH7,5)に溶解した。次いで、あらかじめ同緩衝液
で緩衝化したオリゴ(dT)12−15セルロース(P
Lバイオケミカルズ社)3罰を直径1mのカラムに充填
し、全RNAを供給した。同緩衝液で260 nmの吸
光度が0.05以下になるまで洗浄後、更にo、o I
Mのトリス塩酸緩衝液(0,1MNaC1,0,1%
SDS −1rnMEDTAr5Na含有、−7,5)
で溶出を開始し、260 nmの吸光度が0.05以下
になるまで洗浄した。最後に0.01 Mトリス塩酸緩
衝液(0,1%SDS 、 1 mM EDTA3N
a含有、PH7,5)でポリアデニル酸結@RNA(m
RNA)全カラムから溶出し、7ラクシヨンコレクター
で分取し、260 nmの吸光度が検出される画分を集
合した。2,4,8.24.48時間の各時間培養した
A−C5−8細胞からそれぞれ58゜160.180.
12[]、258μ、?のmRNA ’、、1回収した
。Add a small amount of 0.1% SDS'i to the ethanol precipitate, suspend it, and add an equal volume of extraction buffer (0.5% SDS'i) to the ethanol precipitate.
DS, 0.1 M NaCt, 50 mM sodium acetate, 5 mM EDTA (containing 2Na, 2 days 5.2) and 2 equivalents of water-saturated phenol [containing 0.1% 8-quinolite, 100 mg Tris-HCl buffer ( p) 18
.. 0) Saturated]-chloroform-isoamyl alcohol solution (volume ratio 50:50:1) was added, shaken for 10 minutes, and then centrifuged at 6000 rpm for 10 minutes. The lower layer separated into three layers was removed, and an equal volume of chloroform-isoamyl alcohol solution (volume ratio 50:1) was added to the upper layer and the middle oil. After shaking for 10 minutes, centrifugation was performed at 3000 rpm for 10 minutes to remove all of the lower layer. Removed. This extraction operation using chlorophor L-isoamyl alcohol solution was repeated three times. Add 1 equivalent of 6M sodium acetate (pH 5,2) to the upper layer containing DNA% RNA, sugar, etc., add 2 parts of cold ethanol and leave at 20°C for more than 6 hours, then heat to 150°C.
Centrifugation was performed for 60 minutes at 00 rpm (RPR18-20-ter). Add a small amount of political distilled water to the resulting precipitate. After dissolving, add an equal amount of cold 4M lithium chloride to % 0
Leave at °C overnight, centrifuge at 15,000 rpm for 30 minutes, wash the precipitate with a small amount of 2M lithium chloride, dissolve in sterile distilled water, and add 1/108 of 6M sodium acetate (pH 5,2). After that, 2 equivalents of cold ethanol was added, and the mixture was left at -20°C for 3 hours or more. 15000
Centrifuge for 30 min at rpm to precipitate
M) IJ female acid buffer (0,5M NaCL,
Contains 0.1% SDS, 1mM EDTA3Na,
pH 7.5). Next, oligo (dT) 12-15 cellulose (P
L Biochemicals Co., Ltd.) was packed into a 1 m diameter column to supply total RNA. After washing with the same buffer until the absorbance at 260 nm is 0.05 or less, further o, o I
M Tris-HCl buffer (0.1M NaC1.0.1%
SDS-1rnMEDTAAr5Na-containing, -7,5)
Elution was started and washing was carried out until the absorbance at 260 nm became 0.05 or less. Finally, add 0.01 M Tris-HCl buffer (0.1% SDS, 1 mM EDTA3N)
containing a, pH 7,5) with polyadenylic acid linkage @RNA (m
RNA) All RNA was eluted from the column, fractionated using a 7-lux collector, and fractions with detectable absorbance at 260 nm were collected. 58°160.180. from A-C5-8 cells cultured for 2, 4, 8, 24 and 48 hours, respectively
12[], 258μ, ? One mRNA ', was recovered.
(3) LTに対応するmRNAが卵母細胞で翻訳され
ることの確認
約2年令のアフリカッメガエル(メス、体重50g以上
、日本生物材料センターより購入)に、血清性性腺刺激
ホルモン(獣医杓ピーメツクス注射剤(三共))2[]
OU/匹の割合で大腿部に筋注した。翌日、氷水中につ
けて麻酔した後、腹部?切開して卵母細胞全採取し、M
BS中で単離した。(3) Confirmation that mRNA corresponding to LT is translated in oocytes A two-year-old African frog (female, weighing over 50 g, purchased from the Japan Center for Biological Materials) was injected with serum gonadotropin ( Veterinary scoop Pimex injection (Sankyo)) 2 []
It was injected intramuscularly into the thigh at a rate of OU/mouse. The next day, after being immersed in ice water and anesthetized, the abdomen? Incision was made to collect all oocytes, and M
Isolated in BS.
直径1)以上の卵母X田胞kl(固につき実施例2−(
2)で得たmRNA k K菌類留水に溶解(1m9/
ml)し、50nz(50ng)づつマイクロキャピラ
リーとマイクロインジェクター〔(株)成茂科学器械研
究所表〕全使用して実用顕微鏡下に注入した20個の卵
母細ftMk0.2mlのMBS中23°Cで培養した
。又、同時に滅菌蒸留水のみ53 nlすつ注入したl
卵母細胞20個も0.2−のMBS中23°Cで培養、
した(コントロール〕。Example 2-(
Dissolve the mRNA k obtained in 2) in K fungal distilled water (1 m9/
ml) and injected 20 oocytes (ftMk) under a practical microscope using a microcapillary and a microinjector (Narishige Scientific Instruments Research Institute table) each using a microcapillary and a microinjector (Table 1). Cultured in C. At the same time, 53 nl of sterile distilled water was injected.
Twenty oocytes were also cultured at 23°C in 0.2-MBS.
did (control).
24時間又は48時間培養後の培養上清のLT活性を測
定した結果、48時間培養が卵母細胞の最適培養時間で
あることが判明した。更に、A−C5−8細胞のCon
AとPMAの刺激下での培養時間は、2,4.8.2
4.43時間培養細胞のそれぞれのmRNAの翻訳され
たLT活性が、それぞれ7.8 、4.6 、4.1
、2.7 、0単位/dとなることより%mRNAを取
得するためには、2時間培養がA−05−8細胞の最適
培養時間であることが判明した。コントロールではLT
活性が検出されないことから、LTのmRNAが卵母細
胞中で翻訳されることを確認した。As a result of measuring the LT activity of the culture supernatant after 24 or 48 hours of culture, it was found that 48 hours of culture is the optimal culture time for oocytes. Furthermore, Con of A-C5-8 cells
The culture time under stimulation of A and PMA is 2,4.8.2
The translated LT activities of each mRNA in cells cultured for 4.43 hours were 7.8, 4.6, and 4.1, respectively.
, 2.7, and 0 units/d, indicating that 2-hour culture is the optimal culture time for A-05-8 cells in order to obtain %mRNA. LT in control
Since no activity was detected, it was confirmed that LT mRNA was translated in oocytes.
(4)A−C5−8細胞の大量培養とmRNAの取得実
施例2− (31で決定したCon A及びPMA刺激
下の最適培養条件でA−05−8細胞全培養し3×10
9個の細胞?集めた。この細胞から実施例2−(2)の
方法に準じてm RNAt単離精製し、512漸
μyのmRNA岡分を得た。(4) Mass culture of A-C5-8 cells and acquisition of mRNA Example 2- (Total culture of A-05-8 cells under the optimal culture conditions under Con A and PMA stimulation determined in 31)
9 cells? collected. mRNA was isolated and purified from these cells according to the method of Example 2-(2), and 512 μy of mRNA was obtained.
(5)ショ糖密度勾配遠心法によるmRNAの分画とL
T全mRNA512μ、uk[1,01M)リス塩酸緩
衝液(0,1M EDTA2Na、0.2%SDS含有
、pH7,5) K溶解し・それを同緩衝液に溶解した
5〜30%のショ糖密度勾配溶液5酊上に重層し、RP
R55T−2080−ター(日立製作成製)全使用して
28000 rpmで16時間、15℃下に遠心した。(5) Fractionation of mRNA and L by sucrose density gradient centrifugation
T Total mRNA 512μ, UK [1,01M] Lys-HCl buffer (0,1M EDTA2Na, 0.2% SDS included, pH 7,5) K Dissolved in the same buffer with 5-30% sucrose. Layer the density gradient solution on top of the RP
The whole sample was centrifuged at 28,000 rpm for 16 hours at 15° C. using an R55T-2080-ter (manufactured by Hitachi).
次いで内容物を25本(各216μt)に分画した。各
分画に3M酢酸す) IJウム’r1/10量、冷エタ
ノール全2等量加えて一20’Oで一夜放置し、mRN
Aを沈殿回収した。The contents were then fractionated into 25 tubes (216 μt each). Add 1/10 volume of 3M acetic acid (3M acetic acid) and 2 equivalents of cold ethanol to each fraction, and leave at 20 °C overnight.
A was precipitated and collected.
回収したmRNAを滅菌蒸留水で溶解C0,5m9/創
〕シ、100nt′に実施例2− (31の方法に辿じ
て卵母細胞20個にε人し、0.2だ6のMBSで48
時間培養後、培養上清甲のLT活性を測定した。The recovered mRNA was dissolved in sterile distilled water (C0.5 m9/wound) and 100 nt' was injected into 20 oocytes according to the method of Example 2-31, and mixed with MBS of 0.2 to 6. 48
After culturing for an hour, the LT activity of the culture supernatant was measured.
その結果、分画413が最大のLT活性全示し、沈降定
数の標準マーカー(5S 、 18 S 、 28B)
を用いた検量線から、LTに対応するmRNAの沈降定
数は12.6 S〜14.68であることが+IJ明し
た。As a result, fraction 413 showed the maximum total LT activity and standard markers of sedimentation constant (5S, 18S, 28B)
The standard curve using +IJ revealed that the sedimentation constant of mRNA corresponding to LT was 12.6 S to 14.68.
ここで得られた精製mRNA’に%以下の実験に用いた
。The purified mRNA' obtained here was used in the experiment below.
実施例6
fil eDNAの合成
精製mRNA 5μgk使用し、逆転写酵素システム(
3ZP ) にュー・イングランド・ニュークリア社)
全一部変更してc DNAを合成した。逆転写酵素反応
緩衝液20μt1デオキシヌクレオシド・トリフオスフ
ェート混合物10μt1 リボヌクレアーゼAインヒビ
ター20単位、オリゴ(dT) 12−1810μ&、
600mMのβ−メルカプトエタノール5μ、9.3
2p標識dCTP〔比活性800 C1/ mmot(
100μci))、mRhJA 5 t4. 50単位
トリ骨髄性白血病ウィルス由来逆転写酵素の系で100
μtの容量で、42°01)時間反応させた後、氷冷し
て反応を停止し、遠心後mRNAとcDNAのノ・イブ
リッドを、沸騰水浴中で6分間の熱処理で分離し、氷水
浴中で5分間急冷した。Example 6 Synthesis of fil eDNA Using 5 μgk of purified mRNA, reverse transcriptase system (
3ZP) New England Nuclear Ltd.)
cDNA was synthesized with all partial changes. 20 μt of reverse transcriptase reaction buffer 10 μt of deoxynucleoside triphosphate mixture 20 units of ribonuclease A inhibitor, 12-1810 μt of oligo(dT)
600mM β-mercaptoethanol 5μ, 9.3
2p-labeled dCTP [specific activity 800 C1/mmot (
100 μci)), mRhJA 5 t4. 50 units of avian myeloid leukemia virus-derived reverse transcriptase system and 100
After reacting for 42°01) hours in a volume of μt, the reaction was stopped by cooling on ice, and after centrifugation, the mRNA and cDNA hybrids were separated by heat treatment for 6 minutes in a boiling water bath, and then in an ice water bath. The mixture was rapidly cooled for 5 minutes.
変性した蛋白i12000x、9.2分間の遠心でペレ
ットとし、再度氷冷した。この反応終了液99μtに水
冷下で16.2μtの滅菌蒸留水、DNAポリメラーゼ
■反応緩衝液46.8μt1デオキシヌクレオシド・ト
リフオスフェート混合物10.4μt、 32p標識
dc’rp (800Ci/nmot(100μ丸鳩山
C1)〕及び15.6μtの枦zシー由来DNAポリメ
ラーゼ1(8000単位/ tug ) ′に加え、1
98μtとして、よ(撹拌、遠心後、15°Cで200
時間反応せた。この反応終了液197μtに0.2ME
DTA2Na (39,4μL ) k加え反応を停止
後、1NNaOH(49,25μL ) k加え、65
°Cで1時間アルカリ加温処理を行い、mRNA ′に
分解し、水冷、遠心後にI M ) IJメス酸緩衝液
(49,25μt1pH8,0)及び1 N HCt(
d 9.25μt)全加えて中和した。The denatured protein i12000x was pelleted by centrifugation for 9.2 minutes and cooled on ice again. Add 99 μt of this reaction completed solution to 16.2 μt of sterile distilled water under water cooling, 46.8 μt of DNA polymerase reaction buffer, 10.4 μt of deoxynucleoside triphosphate mixture, 32p labeled dc'rp (800 Ci/nmot (100 μ Maru Hatoyama) C1)] and 15.6 μt of DNA polymerase 1 (8000 units/tug), plus 1
After stirring and centrifuging, incubate at 200 µm at 15°C.
Time reacted. Add 0.2 ME to 197 μt of this reaction-completed solution.
After stopping the reaction by adding DTA2Na (39.4 μL), add 1N NaOH (49.25 μL) and
After 1 hour alkaline heating treatment at °C, it was decomposed into mRNA', cooled with water, and centrifuged.
d 9.25 μt) and neutralized.
これ′に172等量の水飽和フェノールと172等量ノ
クロロホルムーイソアミルアルコール(50:1)で抽
出し、遠心後の上/Mi−分取し、下層に等量の10m
Mトリス塩酸緩衝液(1a o mMNact。This was extracted with 172 equivalents of water-saturated phenol and 172 equivalents of chloroform-isoamyl alcohol (50:1), and after centrifugation, the upper/Mi fraction was separated, and the lower layer was
M Tris-HCl buffer (1a o mMNact.
1 mM EDTA2Na含有、pH8,0) =に加
えて再抽出全行い、その上層も分取した。分取した雨上
TV k等号のクロロホルム−イソアミルアルコールで
抽出し、遠心分離後下層(有機j曽)を除去した。この
抽出操作を4回行った後に等量の水飽和エチルエーテル
で6回抽出を行い、有機層全除去後、6cfC水浴で加
温処理して混在するエチルエーテルを除去した。In addition to 1 mM EDTA (containing 2Na, pH 8,0), re-extraction was performed and the upper layer was also collected. The collected Amejo TV was extracted with chloroform-isoamyl alcohol, and the lower layer (organic) was removed after centrifugation. After performing this extraction operation four times, extraction was performed six times with an equal amount of water-saturated ethyl ether, and after the organic layer was completely removed, the mixture was heated in a 6 cfC water bath to remove the mixed ethyl ether.
この水層を第2ブタノールで濃縮し、終濃度0.01
)AのMgC42と2等量の冷エタノール(−20°C
)を加え、−80°Cで一夜放置した。This aqueous layer was concentrated with sec-butanol to a final concentration of 0.01.
) MgC42 from A and 2 equivalents of cold ethanol (-20°C
) was added and left overnight at -80°C.
1200[IX、9で10分間遠心後の沈殿を減圧下で
乾燥した後、滅菌蒸留水50μtに溶解し、逆転写酵素
反応緩衝液20μt、600mMβ−メルカプトエタノ
ール5μt、デオキシヌクレオシド・トリフオスフェー
ト混合物IDAt及び32p標識dcTP (800
Ci/mmol (’I 0 0 μ Ci
) )k 加えよく撹拌遠心後5μtの前述の逆
転写酵素を庖加後、42℃1時間反応させた。水冷下で
反応を停止し、ヘアピン構造を持つcDNA f得た。After centrifuging for 10 minutes at 1200 [IX, 9, the precipitate was dried under reduced pressure, dissolved in 50 μt of sterile distilled water, and mixed with 20 μt of reverse transcriptase reaction buffer, 5 μt of 600 mM β-mercaptoethanol, and deoxynucleoside/triphosphate mixture IDAt. and 32p-labeled dcTP (800
Ci/mmol ('I 0 0 μ Ci
) ) k After stirring well and centrifuging, 5 μt of the above-mentioned reverse transcriptase was added, and the mixture was reacted at 42° C. for 1 hour. The reaction was stopped under water cooling to obtain cDNA f having a hairpin structure.
上記反応液99μ2に滅菌蒸留水92.1μt、前述の
DNAポリメラーゼI反応緩衝液23.4μt。99μt of the above reaction solution, 92.1μt of sterile distilled water, and 23.4μt of the above-mentioned DNA polymerase I reaction buffer.
S1ヌクレア一ゼ反応緩衝液55μt1アスペルぞルス
・オリーゼ(Aspergillus oryzae
)由来Slヌクレアーゼ(50単位/d)5.5μtを
加え67°0160分間反応し、ヘアピン構造を切断し
て2重鎖cDNA f得た。この溶液に0.1 M ト
Iメス塩酸緩衝液(0,I M EDTA、Na含有、
pH7,5) t46μを加え、ベッド容量20 ru
εのセファクリルS−200カラム(1,0X25C1
n)に供給し、10騙トリス塩酸緩衝液(0,1M N
aC4,1mMEDTA2na含有、pH7,5)にて
溶出した。600μtずつ分画し、空隙率付近に溶出し
た分画を第2ブタノールで濃縮を行い、エタノール沈殿
によりcpNAを回収した。S1 Nuclease reaction buffer 55μt1 Aspergillus oryzae
5.5 μt of Sl nuclease (50 units/d) derived from ) was added and reacted for 67°0160 minutes to cleave the hairpin structure and obtain double-stranded cDNA f. To this solution was added 0.1 M female hydrochloric acid buffer (0.1 M EDTA, containing Na,
pH 7,5) Add t46 μ, bed volume 20 ru
ε Sephacryl S-200 column (1,0X25C1
n) and 10% Tris-HCl buffer (0.1M N).
It was eluted with aC4, containing 1mM EDTA2na, pH 7.5). The fraction was fractionated into 600 μt portions, and the fraction eluted near the porosity was concentrated with secondary butanol, and cpNA was recovered by ethanol precipitation.
(2)オリゴ(dC)テール付加cDNAの調製上記に
より得られた二重鎖cDNAに次の組成の反応緩衝液1
60μt2加えて37°Cで5分間反応させ二重鎖cD
NAにオリゴ(dC)テールを付加させた。(2) Preparation of oligo(dC) tailed cDNA Add reaction buffer 1 of the following composition to the double-stranded cDNA obtained above.
Add 60μt2 and react at 37°C for 5 minutes to remove double-stranded cD.
An oligo(dC) tail was added to NA.
反応緩衝液は、2mMのDTT、5mMのCaCl2.
0.25 mt;i / rILeのBSA、 5μM
ノac’rp、 3H標識dCTP (25Ci/m
mole (15μCi ) :)及び30単位ターミ
ナルデオキシヌクレオチゾルトランス7エラーゼを含有
する0、2Mのカコジル酸カリウム−25mMトリス塩
酸緩衝液(pH6,9)である。The reaction buffer was 2mM DTT, 5mM CaCl2.
0.25 mt;i/rILe BSA, 5 μM
ac'rp, 3H-labeled dCTP (25Ci/m
mole (15 μCi) :) and 30 units of terminal deoxynucleotisol trans7-erase in 0.2M potassium cacodylate-25mM Tris-HCl buffer (pH 6.9).
反応は水冷下で停止させ、等をの水飽和フェノール−ク
ロロホルム−イソアミルアルコール(50:50:1.
l’に加えて抽出し、再度クロロホルム−イソアミルア
ルコール(50:1)で抽出し、40μyの大腸菌由来
リボゾームANA及び1)50量の5 M NaCL
f加え、2等量の冷エタノールを加え、−80°Cで一
夜放置した。遠心分離でオリゴ(dリテール付加c D
NAを回収し、滅菌蒸留水に溶解し、0.5 ng /
μtの濃度とした。The reaction was stopped under water cooling and mixed with water-saturated phenol-chloroform-isoamyl alcohol (50:50:1.
l', extracted again with chloroform-isoamyl alcohol (50:1), and extracted with 40 μy of E. coli ribosomal ANA and 1) 50 amounts of 5 M NaCL.
f and 2 equivalents of cold ethanol were added, and the mixture was left at -80°C overnight. Add oligo(d retail) by centrifugation.
NA was collected and dissolved in sterile distilled water at 0.5 ng/
The concentration was μt.
(3)組換え体プラスミドの作製
オリゴ(dC)テール付加cDNA 1.375 ng
kオリゴ(dc))1o−2oテール付加pBR32
2DNA 10 ng(アマジャム社製つとケアニール
溶液(100mM NaC1; 0.1 mM EDT
A2Nak含有する1 0 mM )リス塩酸緩衝1(
pH7,8))25μを中で65°01)5分間インキ
ュベート後インキュベーターを45°Cに設定し、45
°Cになった後さらに2時間インキュベート後、氷冷し
てアニーリングを行へ組換え体プラスミド溶液を調製し
た。(3) Preparation of recombinant plasmid Oligo (dC) tailed cDNA 1.375 ng
k oligo (dc)) 1o-2o tailed pBR32
2DNA 10 ng (Amarjam Tsutocare Neil solution (100mM NaCl; 0.1mM EDT)
A2Nak containing 10 mM) Lis-HCl buffer 1 (
pH 7,8)) 25μ in 65°01) After incubating for 5 minutes, set the incubator to 45°C,
After the temperature reached °C, the mixture was further incubated for 2 hours, cooled on ice, and subjected to annealing to prepare a recombinant plasmid solution.
−ブロス10m1中、37°Cで吸光度(6500n)
が0.05となるまで培養し、この5m/i3.1%グ
ルコースを含むL−ブロス500 mlに加え、2「C
で吸光度(650nm )が0.6となる1で培養した
。30分間氷冷後、3000 rpm (RpR9−2
0−ター;日立製作成製)、4°Cで5分間遠心して集
菌した。この菌体を冷5 Q mlA CaCl225
0罰に分散し、15分間氷冷した。4°C,5分間、2
50 Orpm (RPR9−2o 1 ) テ集
菌し、20%グリセロールを金山する5 0 mM C
aCl225WLεに分散し、1mlずつ分注し、ドラ
イアイス粉末で凍結後−80°Cに保存した。この保存
菌体分散液を水冷下で解凍し、その0−5m1に前述の
組換え体プラスミド溶液0.15atl及び20 mM
cacz2−6゜mM MnC22−20mM Rb
C1溶液0.15a/、’に混合し、0℃、20分間静
置し、更に室温で10分間静置後、あらかじめ37°C
に温めた0、1%グルコニー含有Lしプ0 ス2.4
yte k添加混合し、37°C,1時間振盪培養を行
った。この培養液の一部を取り、前述の成分の他にテト
ラサイクリン15μi/lttを含有したL−ブロス寒
天平板に広げ67°Cで約12時間培養し、テトラサイ
クリン耐性菌を選択してcDNAライブラリーを作製し
た。- Absorbance (6500n) in 10ml of broth at 37°C
0.05, add this 5m/i to 500 ml of L-broth containing 3.1% glucose, and add 2"C
The cells were cultured at 1, which gave an absorbance (650 nm) of 0.6. After cooling on ice for 30 minutes, 3000 rpm (RpR9-2
(manufactured by Hitachi) and centrifuged at 4°C for 5 minutes to collect bacteria. This bacterial body was cooled with 5 Q mlA CaCl225.
0 punishment and placed on ice for 15 minutes. 4°C, 5 minutes, 2
50 Orpm (RPR9-2o1) Collect bacteria and add 20% glycerol to 50 mM C.
It was dispersed in aCl225WLε, dispensed into 1 ml portions, frozen with dry ice powder, and stored at -80°C. Thaw this preserved bacterial cell dispersion under water cooling, and add 0.15 atl and 20 mM of the above-mentioned recombinant plasmid solution to 0-5 ml of it.
cacz2-6゜mM MnC22-20mM Rb
Mix 0.15a/,' of C1 solution, let it stand at 0℃ for 20 minutes, then let it stand at room temperature for 10 minutes, and then heat it to 37℃ in advance.
0.1% glucony-containing L paste heated to 2.4
ytek was added and mixed, and cultured with shaking at 37°C for 1 hour. A portion of this culture solution was spread on an L-broth agar plate containing 15μi/ltt of tetracycline in addition to the above-mentioned components, and cultured at 67°C for about 12 hours to select tetracycline-resistant bacteria and construct a cDNA library. Created.
(5)ハイブリダイゼーション試験
前記のcDNAライブラリーについて、LTiコードす
るcDNAを含むプラスミドを持つ形質転換体をスクリ
ーニングするために、32P標識合成c DNAプロー
ブ全用いるコロニー・ハイブリダイゼーション試験全行
った。(5) Hybridization test For the above cDNA library, a colony hybridization test using all 32P-labeled synthetic cDNA probes was performed in order to screen for transformants carrying a plasmid containing the cDNA encoding LTi.
合成c DNAプローブは、グレイらがネイチャー(N
ature 312 721 (1984) )に報告
しているLT遺伝子の404から421査目の18塩基
(5’ −oTc′rAcTcccAooTooTc−
3’ )並ひに500から517査目の18塩基に対応
する相補的な塩基配列(5’ −CACATGGAAG
G()C)TACTG−3’ )を化学合成し、その1
6.6 pmO2’k 5単位T 477一シM染m由
来T4ポリヌクレオチドキナーゼとr P ATP
(5μCi/pmole (20μCi ) ) ’
に用いて、50 mM )リス塩酸緩衝液(10mMM
g、C10,5mM DTT 、 0.1 mMスペ
ルミジン、0.1mM EDTA2Na含有、pH7,
6)中、37°C,30分間反応させた。A synthetic c-DNA probe was developed by Gray et al.
The 18th base (5'-oTc'rAcTcccAooTooTc-
3') as well as a complementary base sequence corresponding to the 18 bases from 500 to 517 (5'-CACATGGAAG
Chemically synthesize G()C)TACTG-3'), Part 1
6.6 pmO2'k 5 units T477 IshiM staining m-derived T4 polynucleotide kinase and rP ATP
(5μCi/pmole (20μCi) )'
(50 mM) Lis-HCl buffer (10 mM
g, C10, containing 5mM DTT, 0.1mM spermidine, 0.1mM EDTA2Na, pH 7,
6) The reaction was carried out at 37°C for 30 minutes.
反応はEDTA溶液を添加し、0°Cに氷冷することで
停止した。この2種の32p標緘cDNAゾローブの両
方に弱い条件で、ハイブリダイズする組換大体プラスミ
ド?有する形質転換体を選別した。The reaction was stopped by adding EDTA solution and cooling on ice to 0°C. A recombinant plasmid that hybridizes to both of these two 32p standard cDNA zolobes under weak conditions? The transformants having the following properties were selected.
約1万個のコロニーから6個のコロニーが選ひ出された
。Six colonies were selected from approximately 10,000 colonies.
次にこの選択された6つの菌株がら組換天体プラスミド
全分離し、制限酵素Hi nd ll!で、切断し、ア
カロースケ”ルミ気泳動七行い、ニトロセルロースフィ
ルターにトランスファーし、再度32p標識合成cDN
八プローブと厳しい条件でハイブリダイズし友。その結
果、1個のクローンが選択された。Next, all recombinant celestial plasmids were isolated from the six selected strains, and restriction enzyme Hindll! Then, the cDNA was cleaved, subjected to Akaroske luminophoresis seven times, transferred to a nitrocellulose filter, and re-labeled with 32p.
A friend that hybridized under harsh conditions with the Eight Probes. As a result, one clone was selected.
次にこの選択された酊株についてノ・イブリダイゼーシ
ョントランスレーション試験ヲ、マニアチス(Mani
atis T、 )らのモレキュラー・クローニング(
” Mo1ecu/lar Cloning” 329
(1980)、コールド・スプリング・ハーバ−・ラ
ボラトリ−)に記載の方法に従って行った。この形質転
換体よりシラスミーDNA i抽出し、ニトロセルロー
スフィルター上に加熱変性させた後に固定し、これに実
施例2− (41で得たr、TmRNA k含むmRN
A画分を加え50°Cで3時間反応させ、)1イブリダ
イゼーション?行った。結合したmRNA f溶出回収
した後、た。Next, this selected strain was subjected to a hybridization translation test.
Molecular cloning (
“Mo1ecu/lar Cloning” 329
(1980), Cold Spring Harbor Laboratory). Chilasmi DNA i was extracted from this transformant, heat-denatured and fixed on a nitrocellulose filter, and mRNA containing r and TmRNA k obtained in Example 2-(41)
Add fraction A and react at 50°C for 3 hours.)1 Hybridization? went. After the bound mRNA was eluted and collected, it was removed.
その結果、pLTl 3の場合は10単位/ meのL
T活性が検出されたが、pBR322k使用したコント
ロールではLT活性が認められなかった。As a result, for pLTl 3, 10 units/me of L
Although T activity was detected, LT activity was not observed in the control using pBR322k.
このcDNA f制限酵素H1nduで切断し、アガロ
ースグル電気泳動でその大きさを調べたところ、約’3
5 KbpのcDNA部分を有していた口このcDNA
f含む形質転換体(菌体番号:LT16、クローン化
DNA番号: pLTis )について、クローン化D
NA i単離し後述の方法で塩基配列全決定した。This cDNA was cut with f restriction enzyme H1ndu and its size was examined by agarose gel electrophoresis.
Mouth cDNA had a 5 Kbp cDNA portion
Regarding the transformant containing f (bacteria cell number: LT16, cloned DNA number: pLTis), cloned D
NAi was isolated and the entire base sequence was determined by the method described below.
実施例4
実施例3− +5)で得られた菌株(LT13 ) k
0.1チグルコース及び15μ&/mとテトラサイク
リン含有L−ブロスで培養して菌体を得た。この菌体か
らプラスミドDNA e回収し、次項で述べるM13m
F 8 、9に導入できる制限酵素EcoR1、Sma
I。Example 4 Strain (LT13)k obtained in Example 3-+5)
Bacterial cells were obtained by culturing in L-broth containing 0.1 tiglucose and 15μ/m and tetracycline. Plasmid DNA was recovered from this bacterial body, and M13m, which will be described in the next section, was
Restriction enzymes EcoR1 and Sma that can be introduced into F 8 and 9
I.
Bam Hl、 Pst I 、 Sal I 、 H
ind lの制限#素地図全作製した。第1図参照。Bam Hl, Pst I, Sal I, H
I created all the ind l restriction # raw maps. See Figure 1.
(2)クローン化DNAの塩基配列の決定クローン化D
NAの塩基配列の決定はメツシング(Messing
)らの方法〔ジーン(C)ene ) 19269(1
982))に従ってcDNA断片iM13mp13また
はmp9でサブクローニングした後、サンガー(San
get )らの方法〔プロシーディンゲス・オシ・デ・
ナショナル・アカデミ−・オシ・サイアンシズ・オシ・
デ・USA (Proc、 Nat’1. Acad。(2) Determination of base sequence of cloned DNA Cloning D
Determination of the base sequence of NA is done by Messing
) et al. [Gene (C)ene) 19269 (1
After subcloning in cDNA fragment iM13mp13 or mp9 according to Sanger (San 982))
get) et al.'s method
National Academy of Sciences
De USA (Proc, Nat'1. Acad.
Sci、 USA ) 74 5463 (1977)
ジャーナル・オシ・モレキュラー・バイオロジー(J。Sci, USA) 74 5463 (1977)
Journal of Molecular Biology (J.
Mo1. Biol ) 162 729 (1982
) )のジデオキシ・チェイン・ターミネーション法に
より、プライマーのアニール、 DNAポリメラーゼ
Iのフレノウフラグメントによる相補鎖合成(32P標
鍼dCTP (800Ci/mmol (20μC1)
〕で標識)rルミ気泳動及びオートラジオグラフィーか
ら決定した。Mo1. Biol) 162 729 (1982
)) dideoxy chain termination method, primer annealing and complementary strand synthesis using the Flenow fragment of DNA polymerase I (32P-guided dCTP (800Ci/mmol (20μC1)
) was determined from lumi electrophoresis and autoradiography.
第2図に塩基配列の決定に用いた制限酵素切断部位と塩
基配列を決定した方向及び範囲全矢印で示す。矩形で描
いた部分はLTの翻訳領域をコードする部分を示す。FIG. 2 shows the restriction enzyme cleavage sites used for determining the base sequence and the direction and range in which the base sequence was determined, all indicated by arrows. The rectangular area indicates the area encoding the LT translation region.
その塩基配列は第1表の通りである。第1番目のCの上
流に16個のG連鎖チーダル、第1310番目のTの下
流に18個のC連鎖テールがあり、ベクターと付加する
ときに合成したホモポリマーである。第63から677
番目はLTの前駆体を構成するに必要なポリペゾチド全
コードするト推定される塩基配列である。Its base sequence is shown in Table 1. There are 16 G-linked tails upstream of the 1st C and 18 C-linked tails downstream of the 1310th T, and is a homopolymer synthesized when added to the vector. 63rd to 677th
The number is the predicted nucleotide sequence encoding all the polypezotides necessary to constitute the LT precursor.
このうち第165番目からかLT 71i−コードして
いると考えられ、グレイ(Gray P、W、 )らが
〔ネイチャー(Nature)312 721(198
4))に報告したLTとは、26番目のアミノ酸がTh
r(ACC)であるのに対し、Asn(AJC)である
点が異なっている。C床端アミノ酸(ロイシン〕のコド
ンに続いて、終始コドン(TAG )がある。またペプ
チドコード部位以外に第1〜4番目GCTCがCG()
Gに、第862〜865番目C’ACAがACACに第
1606〜1310査目T()AAAがCCCCTにお
いて異なっている。Of these, it is thought that the LT 71i-code is present from the 165th position, and Gray (P, W, ) et al. [Nature 312 721 (198
4)) The 26th amino acid is Th.
The difference is that it is Asn (AJC) while it is r (ACC). Following the codon for the C-bed end amino acid (leucine), there is a stop codon (TAG).In addition to the peptide coding site, the first to fourth GCTCs are CG()
In G, the 862nd to 865th C'ACA are different from ACAC, and the 1606th to 1310th tests T()AAA are different in CCCCT.
実施例5
−(1)pLT 13のc DNA断片の制限酵素によ
る切断部cDNAの構造から考えられる制限酵素の中で
Nsi l (222番目)並ひにEcoRl (8,
38番目)を使用し、常法に従ってpL’r 13 ’
に切断し、1.5%アガロースデル電気激動?行い61
6 bpのcDNA断片をアガロースゲルから抽出し、
常法によりcDNA断片を精製した。このcDNA断片
はLTのN末鴻側20アミノ酸残基に対応する60塩基
を欠失している。Example 5 - (1) Restriction enzyme cleavage of cDNA fragment of pLT 13 Among the restriction enzymes considered from the structure of cDNA, Nsil (222nd) and EcoRl (8,
38) and pL'r 13' according to the usual method.
Cut into 1.5% agarose del electric upheaval? conduct 61
A 6 bp cDNA fragment was extracted from an agarose gel,
The cDNA fragment was purified by a conventional method. This cDNA fragment lacks 60 bases corresponding to the 20 amino acid residues on the N-terminal side of LT.
ジョン
下記構造の台底オリゴヌクレオチド件千≠≠河1、−一
断片をT 4 DNAリガーゼを用いて66 mM )
IJメス
塩酸緩衝液(p)17.6 )、6.6 mM MgC
l2.10mMDTT 、 I mM ATP中で16
°Cで一夜反応させ、合成オリゴヌクレオチド’i L
TcDNA断片に結合させた。この1反応生成物を常法
により精製した後、EcoRlで消化し623 bpの
EcoR1断片を回収した。The base oligonucleotide of the following structure was prepared using T4 DNA ligase (66 mM) using T4 DNA ligase.
IJ female hydrochloric acid buffer (p) 17.6), 6.6 mM MgC
l2.10mM DTT, 16 in ImM ATP
React overnight at °C, synthesize the oligonucleotide 'iL
It was ligated to a TcDNA fragment. This first reaction product was purified by a conventional method and then digested with EcoRl to recover a 623 bp EcoR1 fragment.
発現ベクターpKK 223−3 (ファルマシア袈)
’1EcoR(で消化した後ウシ腸粘膜白米アルカリフ
ォスファターゼ(ファルマシア製)を用いて50圧トリ
ス塩酸緩衝液(pH9,0)、1 mM MgCl2.
0.1 mM ZnCA2.1鮨スペルミジン中で67
°C130分間反応させ、5′末端の脱リン化を行い、
常法により精製した。以上の処理をほどこしたベクター
と実施例5− (2+で得た6 23 bpのEcoR
(断丈喝j
片を結合させた後、←−乎与JM 105株に常法に従
って形質転換し、アンピシリン耐性により8.700個
の形質転換体を得た。Expression vector pKK 223-3 (Pharmacia)
'1EcoR (bovine intestinal mucosa) using white rice alkaline phosphatase (manufactured by Pharmacia) and 50 pressure Tris-HCl buffer (pH 9,0), 1 mM MgCl2.
67 in 0.1 mM ZnCA2.1 Sushi Spermidine
React for 130 minutes at °C to dephosphorylate the 5' end.
It was purified by a conventional method. The above-treated vector and Example 5- (623 bp EcoR obtained from 2+
After ligating the pieces, they were transformed into ←-Yo JM 105 strain according to a conventional method, and 8,700 transformants were obtained due to ampicillin resistance.
(4)合成cDNADNAプローブスクリーニング実施
例5− (3)で得た形質転換体を実施例3− (51
に示した方法に従って3Kp標識した合成c DNAプ
ローブをコロニーハイブリダイゼーション試験によりス
クリーニングし、150個のコロニーを選択した。この
コロニーのうち無作為に24個を選ひ常法に従ってプラ
スミドを調整し、適当な制限酵素によって切断後、アガ
ロースゲル電気泳動を行い、目的とする断片及びその方
向全検索した。(4) Synthetic cDNA DNA probe screening Example 5-(3) The transformant obtained in Example 3-(51
A 3Kp-labeled synthetic cDNA probe was screened by colony hybridization test according to the method described in , and 150 colonies were selected. Twenty-four of these colonies were randomly selected, a plasmid was prepared according to a conventional method, and after cutting with an appropriate restriction enzyme, agarose gel electrophoresis was performed to search for the target fragment and all its directions.
その結果、目的とする7個のコロニー全選択し、このプ
ラスミドi pDK 10と命名した。pDK I Q
の構築工程全第3図に示す。As a result, all seven target colonies were selected and this plasmid was named i pDK 10. pDK IQ
The entire construction process is shown in Figure 3.
実施例5−(4)で得たプラスミドpDK 10?l−
Hlndlで消化した後BAL 31ヌクレアーゼ(宝
酒造製〕七用いて20 mM トリス塩酸緩衝液(PH
8,[])1)2mMCaCl2.12 mM Mg(
ll’t2.1mM EDTA 、 600mM N
aCt中で30°010分から60分間反応させ、DN
A木端全除去した。次にDNAポリメラーゼ(フレノウ
フラグメント)で平滑末端とした後Ec oR1で消化
し、5%ポリアクリルアミドケ゛ル電気泳動で分画し4
80 bp付近の断片(望ましくは460bp )を回
収した。Plasmid pDK 10 obtained in Example 5-(4)? l-
After digestion with Hlndl, 20 mM Tris-HCl buffer (PH
8, []) 1) 2mMCaCl2.12mM Mg(
ll't2.1mM EDTA, 600mM N
React for 60 minutes at 30°C in aCt, and
A The wood end was completely removed. Next, the ends were blunt-ended with DNA polymerase (Frenow fragment), digested with EcoR1, and fractionated by 5% polyacrylamide gel electrophoresis.
A fragment around 80 bp (preferably 460 bp) was recovered.
実施例5− (51で得たDNAIfr片とBind
lリンカ−(全酒造製)全結合させた後、Hind l
で消化し、常法により私製した。Example 5- (DNA Ifr piece obtained in 51 and Bind
Hindl linker (manufactured by Zenshuzo Co., Ltd.) After complete linkage, Hindl
It was digested and produced privately using a conventional method.
pKK 223−3 k FCORI並びにHind
lで消化ルミ気泳動により分離し、常法により精製≠寺
〇実施例5− (6)で得たEcoRI −Hind
I DNA断片と結合し、LT cDNA断片?有する
ベクター全構築しpDK 1)の構築工程を第4図に示
す。pKK 223-3 k FCORI and Hind
EcoRI-Hind obtained in Example 5-(6)
Combines with I DNA fragment and LT cDNA fragment? FIG. 4 shows the entire construction process of pDK1).
実施例5− (7)で得たプラスミドf Bam Hl
並ひにPvu [で消化した後、アガロースゲル電気泳
動によりLT cDNA f含む断片上分画、精製した
。一方プラスミドpAT 153 (アマジャム社より
購入)も同様にBan H1並ひにPvu Iで消化し
た後、DNA複製開始点を含む断片を分画、精製した。Example 5 - Plasmid f Bam Hl obtained in (7)
After digestion with Pvu, the fragment containing LT cDNA f was fractionated and purified by agarose gel electrophoresis. On the other hand, plasmid pAT 153 (purchased from Amajam) was similarly digested with Ban H1 and Pvu I, and the fragment containing the DNA replication origin was fractionated and purified.
上記の2釉類のBan Hl −Pvu I断片全ライ
ク”−シ匁鳴の
ヨンさせた後、常法により≠!工=對JM 105aに
尋人し、アンぎシリン耐性により、4300個の形質転
換体?選択した。この中から無作為に24個の形質転換
体を選択し、常法に従ってプラスミドDNA k釉°製
した。適当な制限酵素により、目的とするLTcDNA
断片の数及び方向について検索した。その結果目的とす
る24個のコロニー全pDK 12の構築工程を第5図
に示す。After the Ban Hl-Pvu I fragments of the above two glazes were dried, they were transferred to JM 105a using the usual method, and 4,300 traits were obtained due to the anti-silicin resistance. Transformants were selected. Twenty-four transformants were selected at random from among them, and plasmid DNA was prepared using a conventional method. The desired LT cDNA was isolated using an appropriate restriction enzyme.
The number and orientation of fragments were searched. As a result, the steps for constructing all 24 colonies of pDK 12 are shown in FIG.
?アンピシリン50μ9/ynl、プロリンを除り19
$種類の必須アミノ酸を含むM9培地で一投前培養を行
った。翌日培養液が10倍希釈になるようにアンピシリ
ン25μ&/dk含むLB培地(組成: I Asクバ
クトートリプトン10.L バクトー酵母!*ス5F
NaC1)o9:pH7〜7.5〕に接種した。? Ampicillin 50 μ9/ynl, excluding proline 19
One preculture was performed in M9 medium containing $1000 essential amino acids. The next day, add LB medium containing 25 μ/dk of ampicillin so that the culture solution is diluted 10 times (composition:
NaC1)o9: pH 7-7.5].
A55゜=0.6に達した後
IPTC) i最終濃度1mMになるように加え、ざら
にfi−ssa = 1まで培養した。培養物を超音波
処理によって破壊し、細胞抽出物のLT活性全測定した
。After reaching A55 = 0.6, IPTC) was added to a final concentration of 1 mM, and cultured until fi-ssa = 1. Cultures were disrupted by sonication and total LT activity of cell extracts was measured.
培養物1)1Ll当り約3.5 X 105単位の活性
が得られた。Culture 1) Approximately 3.5 x 105 units of activity per Ll were obtained.
pDK 12で形質1決した JM’llJコ
久株をアンピシリン50μ9/me1 プロリンを除く
19槙類の必須アミノ酸を含むM9培地で一夜培養し、
この培養液全20倍量の以下に示す培地で培養した。The JM'llJ Koku strain, which had been completely transformed with pDK 12, was cultured overnight in M9 medium containing ampicillin 50μ9/me1 and 19 essential amino acids excluding proline.
The cells were cultured in the following medium containing 20 times the total amount of this culture solution.
Na2HPO47,0
KH2P○46・0
(NHa)2sO45・0
Na−citrate 1.0Mg
SO40,1
Glucose 25.OCas
amino acid 4,0Yeas
t Extract 4.OThiam
ine 0.1アンピシリン
0.02 pH7,5培地のA350が
約10に達した時、IPT() ’i最終濃度5吐にな
るように加えA350が60に達する1で培養した。培
養液全限外濾過及び遠心分離によジ回収し、菌体約75
0 、ji’ (wet ) f回収した。Na2HPO47.0 KH2P○46.0 (NHa)2sO45.0 Na-citrate 1.0Mg
SO40,1 Glucose 25. OCas
amino acid 4,0Yeas
t Extract 4. OThiam
ine 0.1 ampicillin
When the A350 of the 0.02 pH 7.5 medium reached approximately 10, IPT()'i was added to a final concentration of 5 ml and cultured with 1 to reach the A350 of 60. The entire culture solution was collected by ultrafiltration and centrifugation, and approximately 75 bacterial cells were collected.
0, ji' (wet) f were collected.
菌体t 50 mM )リス塩酸緩衝液(pH8,0)
、60mM NaCt及び0.01mM(p−アミジノ
フェニル)メタンスルホニルフルオライド塩酸塩((p
−Amidinophenyl ) methanes
ulfonyl F’1uorideHydroch’
1oride ;和光紬薬製) 2;000m7に懸濁
し、ダイノミルにより破砕後、遠心分離により粗抽出液
を得た。粗抽出液3.700 dの全LT活性は60ロ
X 1012単位、比活性は5X10’単位/■タンパ
ク質であった。Bacterial cells t 50mM) Liss-HCl buffer (pH 8.0)
, 60mM NaCt and 0.01mM (p-amidinophenyl)methanesulfonyl fluoride hydrochloride ((p
-Amidinophenyl) methanes
ulfonyl F'1uorideHydroch'
1oride; manufactured by Wako Tsumugi Pharmaceutical Co., Ltd.) 2;000 m7, and after crushing with Dynomill, a crude extract was obtained by centrifugation. The total LT activity of 3.700 d of crude extract was 60 x 1012 units, and the specific activity was 5 x 10' units/■ protein.
実施例8
(1)硫安分画
実施例7の粗抽出液3.700mgに硫酸アンモニウム
に5°Cで40%飽和になるように添加し、60分後、
遠心分離し、沈殿部’z 5 mM IJン酸バッファ
ー(pi−17,8)C以下PBと略す、1500+x
Jに溶解し、限外濃縮器を用いて濃縮−希釈ケくり看
返し脱塩を行い硫安塩析試料とした。硫安塩析試料18
5m1の全LT活性は5.2 x 1012単位、比活
性は3.7 x I Q6単位/mQタンパク質であっ
た。Example 8 (1) Ammonium sulfate fractionation To 3.700 mg of the crude extract of Example 7, ammonium sulfate was added to 40% saturation at 5°C, and after 60 minutes,
Centrifuge and precipitate the precipitate with 5 mM IJ acid buffer (pi-17,8) C, hereinafter abbreviated as PB, 1500+x
The sample was dissolved in J and subjected to concentration-dilution and repeated desalination using an ultraconcentrator to obtain an ammonium sulfate salting-out sample. Ammonium sulfate salting out sample 18
The total LT activity of 5ml was 5.2 x 1012 units and the specific activity was 3.7 x I Q6 units/mQ protein.
s mM pEl (pH7,8)であらかじめ平衡化
したDEAE−セファローズCL −6B (ファルマ
シア社つのカラム(4,5cmX 5 [1cm )に
硫安塩析試料184dk付じ、次いで5 mM PB
3.Otでカラムを洗浄したのち食塩濃度0から0.6
Mまで連続的に上昇させ溶出した。溶出液は100mJ
すつ分画し、各画分のLT活性を測定し、活性全有する
画分を回収した。回収液約3.Ot k分画分子1t1
o、口00の限外濾過膜(ミリポア社’A)k用いて1
70WL!!に凝縮した。この濃縮液k DEAE分画
液とした。DEAE-Sepharose CL-6B (Pharmacia Co., Ltd. column (4.5 cm x 5 [1 cm)] pre-equilibrated with ammonium sulfate salting sample 184 dk was pre-equilibrated with s mM pEl (pH 7,8), and then 5 mM PB
3. After washing the column with Ot, the salt concentration was adjusted from 0 to 0.6.
It was eluted by increasing the concentration continuously to M. Eluent is 100mJ
The LT activity of each fraction was measured, and the fractions having all the activities were collected. Recovered liquid approx. 3. Ot k fraction molecule 1t1
1 using an ultrafiltration membrane (Millipore'A) with a diameter of 0.
70WL! ! condensed into. This concentrated solution was used as a DEAE fraction solution.
DEAE分画液の、全LT活性は2.9 X 10i2
単位、比活性は2.4 X 10’単位/mqタンパク
質であった。The total LT activity of DEAE fraction is 2.9 x 10i2
unit, specific activity was 2.4 x 10' units/mq protein.
PBで緩衝化した生理食塩水であらかじめ平衡化したフ
ェニルセファローズCL −6B (ファルマシア社〕
のカラム(5,0cfnX i 5cfn)にDEAE
分画液1691n君を吸着させ、次いでエチレングリコ
ールろ口%を含む10mMPB(pH7,8)6001
で洗浄した後、エチレングリコール濃度を70第2表
LTポリペプチドのアミノ酸組成ILE
2・86
VAL 8.9 9LEU
22.0 21PHE
io、1 10cys <
o、i 。Phenyl Sepharose CL-6B (Pharmacia) pre-equilibrated with saline buffered with PB
column (5,0cfnX i 5cfn)
Adsorb fraction 1691n, then 10mMPB (pH 7,8) 6001 containing ethylene glycol filtrate%.
After washing with
Amino acid composition of LT polypeptide ILE
2.86 VAL 8.9 9LEU
22.0 21PHE
io, 1 10cys <
o,i.
MET 3.1 3ALA
1).8 12GLY
9 、1 9THR7、37
TRP 1.7 2SER19
,420
’rYR6、87
PRO12,21)
HIS10.19
LYS 5.0 5訊o
1.9 2分析値は、LTポリペプ
チドをコードi 、B DNAの塩基配列から推測され
たアミノ酸組成と良(一致した。MET 3.1 3ALA
1). 8 12GLY
9, 1 9THR7, 37 TRP 1.7 2SER19
,420'rYR6,87 PRO12,21) HIS10.19 LYS 5.0 5Question
The 1.92 analysis value was in good agreement with the amino acid composition inferred from the base sequence of the DNA encoding the LT polypeptide.
2 アミノ酸配列
N末端アミノ酸配列はエドマン(Edman )法(P
、 Edman ;アーキテクチュア バイオケミスト
リイ アンド バイオフィジックス(Arch。2 Amino acid sequence The N-terminal amino acid sequence was determined using the Edman method (P
, Edman; Architecture, Biochemistry and Biophysics (Arch.
Biochem、 Biophys、 ) 、 22
475 (1949))により測定した。Biochem, Biophys, ), 22
475 (1949)).
LTポリペプチド(約100μg)kフェニルインチオ
シアネートとカップリング反応させ、次いでN末端アミ
ノ酸を2−アニリノ−5−チアゾリノン誘導体として切
断し、更にフェニルチオヒダントイン−アミノ酸に変換
し、これに018逆相カラムを用いたHPLC(ウォー
ターズ社製)により同定しN床端部分のアミノ酸を決定
した。さらに、この操作を順次くり返すことにより、N
末端部分のアミノ酸配列を決定した。LT polypeptide (approximately 100 μg) was subjected to a coupling reaction with phenylthiocyanate, and then the N-terminal amino acid was cleaved as a 2-anilino-5-thiazolinone derivative, further converted to phenylthiohydantoin-amino acid, and this was subjected to a 018 reverse phase column. The amino acids at the end of the N bed were determined by HPLC (manufactured by Waters). Furthermore, by repeating this operation sequentially, N
The amino acid sequence of the terminal portion was determined.
この結果、LTポリペプチドのN床端部分のアミノ酸配
列は
MET−HIS−LEU−ALA−HIS−3ER−A
SN−LEU−LYS−PRO−ALA−ALA−HI
S−LgU−ILE−OLY−ASP−であった。As a result, the amino acid sequence of the N-bed end portion of the LT polypeptide is MET-HIS-LEU-ALA-HIS-3ER-A
SN-LEU-LYS-PRO-ALA-ALA-HI
It was S-LgU-ILE-OLY-ASP-.
以上に説明した様に、得られた本発明の生理活性ポリペ
プチドは、リンホトキシン活性をもち、実質的に不純物
を含まない新規な生理活性ポリペプチドである。また本
発明の生理活性ポリペブチに、余分のメチオニンの付加
を防ぐことができる。As explained above, the obtained physiologically active polypeptide of the present invention is a novel physiologically active polypeptide that has lymphotoxin activity and is substantially free of impurities. Further, addition of excess methionine to the bioactive polypeptide of the present invention can be prevented.
第1図は、本発明実施例による制限酵素地図を示す概路
線図、
第2図は、本発明実施例による塩基配列の決定に用いた
制限酵素切断部位と塩基配列を決定した方向および範囲
を示す概路線図である。
B −−−Bam Hl 、 E ・−gcoR[P
・・−Pst I第6図は実施例5のtacプロモー
ター付形質発現プラスミドpDK 40の構築工程を示
す。矢印はプロモーターの働(方向を示す口
第4図は実施例5のtacプロモーター付形質発現プラ
スミドpDK1)の構築工程を示す。矢印はプロモータ
ーの働く方向を示す。
特許出願人 電気化学工業株式会社
第1図
第2図
第3図
ILT13
↓Ns l I+EcoRI
↓しigation
↓EcoRI
第4図
、lBAL31
jDHApolymerase I (Klenow
Frugmenむン↓EcoRI
460bp付近のDNA断片を回収
第5図
pDKll pAT153
手続補正書
手続補正部8月21日Figure 1 is a schematic diagram showing a restriction enzyme map according to an example of the present invention, and Figure 2 shows the restriction enzyme cleavage sites used in determining a base sequence according to an example of the present invention, and the direction and range in which the base sequence was determined. It is a rough route map shown. B---Bam Hl, E・-gcoR[P
...-Pst I FIG. 6 shows the construction steps of the tac promoter-equipped expression plasmid pDK 40 of Example 5. The arrow indicates the function of the promoter (the direction shown in FIG. 4 is the construction step of the tac promoter-equipped expression plasmid pDK1 of Example 5). Arrows indicate the direction of promoter action. Patent applicant Denki Kagaku Kogyo Co., Ltd. Figure 1 Figure 2 Figure 3 ILT13 ↓Ns l I+EcoRI ↓Sigation ↓EcoRI Figure 4, lBAL31 jDHApolymerase I (Klenow
Frugmenmun↓EcoRI Recovering DNA fragment around 460bp Figure 5 pDKll pAT153 Procedural Amendment Procedure Amendment Department August 21st
Claims (1)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61151773A JPS638399A (en) | 1986-06-30 | 1986-06-30 | Physiologically active polypeptide |
DE19863686148 DE3686148T2 (en) | 1985-12-24 | 1986-12-23 | LYMPHOTOXIN GENE, METHOD FOR THE PRODUCTION THEREOF AND LYMPHOTOXIN. |
EP86310109A EP0230781B1 (en) | 1985-12-24 | 1986-12-23 | Lymphotoxin gene, method for its production, and lymphotoxin |
US07/733,974 US5403725A (en) | 1985-12-24 | 1991-07-22 | Method for production of lymphotoxin (TNFB) in cell line A-C5-8 |
US08/243,168 US5776446A (en) | 1985-12-24 | 1994-05-16 | Human lymphotoxin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61151773A JPS638399A (en) | 1986-06-30 | 1986-06-30 | Physiologically active polypeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS638399A true JPS638399A (en) | 1988-01-14 |
Family
ID=15525980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61151773A Pending JPS638399A (en) | 1985-12-24 | 1986-06-30 | Physiologically active polypeptide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS638399A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02483A (en) * | 1987-10-28 | 1990-01-05 | Eisai Co Ltd | Recombined lymphotoxin derivative |
JPH03106821A (en) * | 1989-09-20 | 1991-05-07 | Denki Kagaku Kogyo Kk | Antitumor agent |
US5188969A (en) * | 1988-06-20 | 1993-02-23 | Denki Kagaku Kogyo Kabushiki Kaisha | Monoclonal antibody to human lymphotoxin and use thereof |
US5639728A (en) * | 1993-10-01 | 1997-06-17 | Kaji; Akira | Antineoplastic peptide |
-
1986
- 1986-06-30 JP JP61151773A patent/JPS638399A/en active Pending
Non-Patent Citations (1)
Title |
---|
JOURNAL OF CELLULAR BIOCHEMISTRY=1985 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02483A (en) * | 1987-10-28 | 1990-01-05 | Eisai Co Ltd | Recombined lymphotoxin derivative |
US5188969A (en) * | 1988-06-20 | 1993-02-23 | Denki Kagaku Kogyo Kabushiki Kaisha | Monoclonal antibody to human lymphotoxin and use thereof |
JPH03106821A (en) * | 1989-09-20 | 1991-05-07 | Denki Kagaku Kogyo Kk | Antitumor agent |
US5639728A (en) * | 1993-10-01 | 1997-06-17 | Kaji; Akira | Antineoplastic peptide |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2515308B2 (en) | Human immune interferon | |
JP2561255B2 (en) | Recombinant colony-stimulating factor ▲ below- ▼ 1 | |
JP2999579B2 (en) | DNA and its uses | |
JPH09135690A (en) | Expression vector capable of expressing endothelial cell growth factor and transformed cell thereof | |
JPH025760B2 (en) | ||
JPH0240080B2 (en) | ||
HU209152B (en) | Method for producing human interferon protein of high purity and pharmaceutical preparative containing it | |
JPH0866194A (en) | Gene encoding human tumor necrosis factor mutein | |
Blechynden et al. | Sequence and polymorphism analysis of the murine gene encoding histidyl-tRNA synthetase | |
JPS638399A (en) | Physiologically active polypeptide | |
JP2634132B2 (en) | New peptide | |
JP2548204B2 (en) | New bioactive polypeptide | |
CN109942694A (en) | Grass carp Akirin1 gene, encoded protein and its application | |
EP0230781B1 (en) | Lymphotoxin gene, method for its production, and lymphotoxin | |
JPS638398A (en) | Physiologically active polypeptide | |
JPH02195888A (en) | Recombinant dna body containing gene coding polypeptide having human interleukin-2 and procaryote cell transformed by the same recombinant dna body | |
JPS62151182A (en) | Gene and production thereof | |
JPS61502514A (en) | growth related hormones | |
JPS61291598A (en) | Fish calcitonin derivative and method for producing the same | |
JP3391484B2 (en) | DNA containing a region having promoter activity of human endothelin-2 gene | |
JPH057995B2 (en) | ||
JPH051800B2 (en) | ||
JPS6291198A (en) | Polypeptides with antitumor effects | |
JPH051799B2 (en) | ||
JPS61271222A (en) | Human interleukine 1 polypeptide and derivative thereof |